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ABSTRACT 
Introduction 
Controversy continues over the extent of surgical resection margin required to minimize the 
risk of local recurrence (LR) in breast conserving therapy (BCT) for stage I and II breast cancer. 
This thesis explores whether or not a narrow (less than or equal to 2 mm) but negative resection 
margin in BCT for stage I and II breast cancer affects LR.   
Methodology 
To address the question, all patients registered at the Saskatoon Cancer Center between 
January 1, 1991 and December 31, 2000 with a diagnosis of stage I or II invasive duct carcinoma 
of the breast treated with BCT were examined. All charts and pathology reports were reviewed 
with a review of the pathology for all cases where the resection margin was unclear in the 
original report. Other factors know or thought to effect LR (age, radiation boost, grade, extensive 
duct carcinoma in situ, ER/PR receptor status, tumor size, and systemic adjuvant therapy) were 
considered in the statistical analysis.  
Results 
Amongst the 200 narrow margin cases 19 LR were detected (19/200=9.5%) while 52 LR were 
detected in the 491 wide margin cases (52/491=10.6%). This difference was not statistically 
significant. 
Conclusions 
A narrow (less than or equal to 2 mm) surgical resection margin does not result in an increase 
in local recurrence compared to a surgical resection margin greater than 2 mm in breast 
conserving therapy for early stage duct carcinoma and does not warrant re-excision. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Overview 
The research question that is being addressed in this manuscript arose from the author’s 
clinical surgical practice. For many years the standard of care for performing breast conserving 
surgery in Saskatoon was to remove the cancer with at least some surrounding tissue. Subsequent 
radiation treatment was given to minimize local recurrence. During that era the patient was 
submitted to a re-excision only in the event of a positive surgical resection margin. More recently 
newer radiation oncologists at the Saskatoon Cancer Agency began to request a re-excision for 
all tumors in which the original margin was less than 2 mm. This change in practice resulted in 
many more women undergoing a second or even third operation. The evidence to support that 
practice change was insufficient to warrant the change from the author’s perspective and served 
as the impetus for conducting this research.  
Current evidence suggests that breast conserving therapy (BCT), which includes wide local 
excision and post-operative adjuvant irradiation, is equivalent to mastectomy with respect to 
overall survival for early stage breast cancer. There is, however, an increased local recurrence 
rate with BCT in the order of approximately 1% per year compared with an overall local 
recurrence at 10 years with modified radical mastectomy of about 1%. Subsequent management 
of a local recurrence frequently results in a completion mastectomy with an attendant decreased 
quality of life.  There is also evidence to suggest that while the overall survival between patients 
who undergo a mastectomy or BCT is equivalent the survival of the subset of individuals who do 
have a local recurrence is lower. Minimizing the incidence of local recurrence would therefore 
be desirable. 
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The conventional definition of a negative surgical margin in North America, as defined in the 
original work done by Fisher, is “no tumor at the inked margin”. European trials conducted 
around the same time required a wider surgical resection margin. The Milan trial required a 2-3 
cm margin while the European Organization for Research and Treatment of Cancer (EORTC) 
trial required a 1 cm surgical resection margin. In recent years there has been some concern 
expressed that a narrow surgical resection margin (defined as less than or equal to 2mm) may be 
associated with an increased local recurrence rate compared with a surgical resection margin 
greater than 2mm. The literature in this area is inconclusive. This thesis work is designed to 
contribute evidence towards the resolution of this issue. 
The article that resulted from this thesis work and was published in the Journal of Surgical 
Oncology in March of 2011 is found in Appendix A. 
1.2 Objective 
The objective of this thesis is to determine if a narrow (less than but equal to 2 mm), but 
negative, surgical resection margin in BCT done for early stage breast cancer results in an 
increase in local recurrence.  
1.3 Hypothesis 
The hypothesis is that a narrow (less than or equal to 2mm) surgical resection margin in BCT 
done for early stage breast cancer does not result in an increased local recurrence rate.  
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CHAPTER 2 
LITERATURE SURVEY 
 
2.1 Introduction 
Two separate critical reviews were conducted to support this thesis work. Theories about what 
causes cancer are critically necessary to inform research questions that have to do with the 
management of cancer and as such the first review was, necessarily, a review of the current 
theories of oncogenesis. For this survey the Pub Med and Google Scholar databases were 
searched using the key words oncogenesis, tumerogenesis, and carcinogenesis and limited to the 
reviews in the last 5 years in the English language. A total of 4,329 citations were generated, of 
which 237 were used in the critical review of the theories of oncogenesis. 
The second review was a more specific review of the evidence that currently exists about 
local recurrence in early stage breast cancer patients treated with breast conserving therapy. This 
review was conducted to inform the specific research question that makes up the main portion of 
this thesis work. For the survey about local recurrence in early stage breast cancer the Pub Med 
database was first searched using the following key words: breast neoplasms, neoplasm 
recurrence, local, and mastectomy, segmental. This search strategy generated 6768 citations of 
which 983 were considered relevant to the subject matter and reviewed in detail. 
2.2 Literature Survey of Oncogenesis 
Oncogenesis refers to our understanding of what causes cancer. Sonnenschein and Soto 
lament the vast quantities of research performed in the quest to eradicate cancer done in the 
absence of a theoretical framework. (1) They quote Leslie Foulds as commenting that 
“experimental analysis has produced an alarming mass of empirical facts without providing an 
adequate language for their communication or effective concepts for their synthesis” in making 
their case that the premises and perspectives that researchers bring to their research should be 
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made a priori “as premises are not testable, and data are not free of the theoretical frame used to 
gather them”.   
By far the most well know and accepted theory of oncogenesis is the gene mutation theory. 
Peyton Rous laid the groundwork for this theory in 1911 when he identified a spindle cell 
sarcoma in chickens that was transplantable from one chicken to another.(2) A filtrate of a 
malignant tumor was used to transmit the cancer from one bird to another. In time it was 
discovered that the rous sarcoma virus (RSV) was the infectious agent responsible. Years later 
Bishop hypothesized that “normal cells may bear the seeds of their own destruction in the form 
of cancer genes. The activities of these genes may represent the final common pathway by which 
many carcinogens act. Cancer genes may not be unwanted guests but essential constituents of the 
cell’s genetic apparatus, betraying the cell only when their structure or control is distributed by 
carcinogens.”(3) He hypothesized that cancer-causing genes (oncogenes) that were carried by 
tumor causing viruses had counterparts in the genomes of all vertebrate cells. He termed these 
normal counterparts proto-oncogenes. A multitude of studies have since demonstrated the 
existence of a family of viral oncogenes that can be transmitted either via DNA or RNA 
viruses.(4) DNA viruses replicate their DNA along with host genome and promote neoplastic 
transformation in conjunction with environmental and genetic factors. RNA tumor viruses on the 
other hand integrate their RNA genomes into the genome of the host cell inducing neoplastic 
transformation by integrating its genome near the coding sequence for a proto-oncogene. 
Through multiple rounds of infection and genome replication mutations occur in the proto-
oncogene resulting in neoplastic transformation. Bishop’s initial theory has since been refined 
but the basic tenant is that carcinogens of one sort or another interact with DNA resulting in 
irreversible changes in the gene (point mutations), which predispose the cells to malignant 
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transformation. The gene mutations occur in 2 classes of regulatory genes, oncogenes (positive 
regulators) and tumor suppressor genes (negative regulators). Modifications of the gene mutation 
theory include Knudson’s two hit hypothesis, and several multistep hypothesis such as those 
proposed by Weinberg, Barrett and Vogelstein.(5-8)  Of these the Vogelstein model has gained 
the most popularity. In it Vogelstein and colleagues postulated a progressive model, which 
includes both activation of oncogenes and the loss of tumor suppressor genes. Feinberg 
introduced the concept of epigenetic changes that allows for non-mutational stable changes to 
occur in the cellular genome and that can contribute to cancer transformation.(9) 
Duesberg et al. advanced a new theory that suggests that a carcinogen initiates carcinogenesis 
via a preneoplastic aneuploidy event.(10)  According to this theory, while the majority of 
aneuploidy cells die following cell division the rare one survives. The surviving aneuploidy cell 
then initiates an “autocatalytic karyotype evolution” that generates new chromosomal variants 
including, eventually, a neoplastic aneuploidy cell.  
Early work done by McCullock and Till resulted in the development of what McCulloch 
terms “modern hematology”, which includes the concept of the stem cell.(11) In 1963 they 
suggested that stem cells have two defining properties—self renewal and differentiation.(12) 
Initially it was thought that stem cells functioned only in obligatory renewal systems such as the 
hematopoietic, epithelial mucosal or skin systems. More recently findings from several 
laboratories demonstrate the existence of adult stem cells with the potential to differentiate and 
produce the functional cells of several organs.(11) These cells are potential targets for 
carcinogenic events.  
In 1997 Bonnet and Dick first coined the term cancer stem cells (CSC) to describe a small 
population of leukemic cells that have the ability to self-renew.(13) With further evidence to 
 6 
support the concept a new theory of oncogenesis—the cancer stem cell theory—has emerged. 
The theory states that only a small subset of cancer stem cells exist within a tumor and cause the 
propagation of a given tumor.(14) These cancer stem cells have the capacity to self-renew and to 
form the heterogeneous lineages of cancer cells that comprise the tumor. In the CSC theory it is 
believed that non-tumorigenic cells in a cancer are derived from parent tumorigenic cells in a 
hierarchical and stable manner that parallels in concept the development of differentiated cells 
from stem cells in normal tissue development.(13) The CSC theory does not, as the name 
implies, refer to the cell from which the cancer arises. In fact the CSC theory does not require 
that tumorigenic cells be similar phenotypically, genetically, epigenetically or functionally to 
normal stem cells of the same organ.  What it does require is for tumorigenic cells to be 
infrequent, to be capable of generating both more tumorigenic cells as well as the larger 
population of non-tumorigenic cells in a stable and hierarchical manner and to be separable from 
non-tumorigenic cells. In the CSC theory it is thought that malignant transformation is likely to 
occur through dysregulation of the self-renewal pathways.(15)  
There is significant interest in, and evidence to support, the CSC theory. Several implications 
flow from this theory. CSC share many properties with normal stem cells, namely a self-renewal 
capacity, resistance to radiation and many chemotherapeutic agents and potentially the ability to 
interconvert (the ability to change between different functional states—changing their 
proliferative and differentiation fates in response to environmental causes).(16) Self-renewal is 
the property that allows stem cells to produce at least one progenic cell with similar 
developmental potential. When stem cells divide one daughter is an exact copy of the original 
and the other differentiates. It is interesting that many of the genes responsible for self-renewal 
are also oncogenes and many genes that inhibit it are tumor suppressor genes.(13) Stem cell 
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research has shown us that self-renewal is controlled by several processes such as the hedgehog 
pathway, the notch pathway, Wnt signaling and NF-kB signaling.(13-15) 
Sonnenschein and Soto suggest that all of the above theories of oncogenesis are variations on 
a theme, that theme being cell proliferation control as the cause of cancer. (1)  They then suggest 
that there exists a new emerging theory centered at the tissue level and called the tissue 
organizational field theory (TOFT) which views oncogenesis more like “a process akin to 
organogenesis gone awry.” The premises underlying this theory are that oncogenesis is a 
problem of tissue organization, comparable to organogenesis during early development, and that 
proliferation is the default state of all cells. In the TOFT model carcinogens disrupt reciprocal 
interactions between cells that maintain tissue organization, tissue repair and local homeostasis 
and result in cells being allowed to exercise their innate ability to proliferate and migrate.  
The various theories of oncogenesis need not be thought of as mutually exclusive. As 
Sonnenschein and Soto point out there is a significant amount of overlap in the various somatic 
mutation theories.(1) Even between those various theories and TOFT there is considerable 
overlap emerging when one considers the epigenetic contributions to oncogenesis in the gene 
mutation theory and the microenvironment considerations in the CSC theory. All of these 
theories agree that the 5% of malignancies that are hereditary cancers are caused by germline 
DNA mutations.   It is quite conceivable that, while there appears to be considerable 
philosophical distance between the different theories, some form of hybrid theory incorporating 
these will emerge. The very heterogeneous and complex nature of cancer would make that 
thinking very congruent. That there is convincing evidence to support each theoretical model 
also supports that possibility. At the very least information gathered under the rubric of one 
theory or the other might be used to help inform the overall understanding of the problem.  
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2.3 Literature Survey of the Evidence Surrounding Local Recurrence in Early Stage Breast 
Cancer Treated with Breast Conserving Therapy. 
2.3.1 History 
Halsted proposed that a radical resection was necessary to cure breast cancer. The theory 
underpinning Halsted’s radical mastectomy suggested that breast cancer spreads via lymphatics 
in an orderly and defined manner and that hematologic spread was of little to no significance.(17, 
18) With that theoretical belief Halsted advocated radical surgery, which included removal of the 
breast, the underlying pectoralis major muscle and the axillary lymphatics. Research, beginning 
in 1959, led to the formation of an alternative hypothesis of spread that argued that cancer is a 
systemic disease that involves a complex spectrum of host-tumor interrelations and that 
variations in local regional therapy are unlikely to substantially affect survival. The differences 
between the two theories as articulated by Fisher are summarized in table 2.1.(17) In 1971 the 
National Surgical Adjuvant Breast and Bowel Project (NSABP) launched its B-04 clinical trial. 
In this trial, first published in 1977, 1700 women were randomly assigned to one of three 
surgical treatment arms—total (simple) mastectomy and local-regional radiation, total 
mastectomy alone, and radical mastectomy.(19)  Fifteen year follow-up showed no significant 
difference in treatment failure, distant metastasis or survival. Consequently a 1979 National 
Institute of Health consensus conference concluded that total mastectomy and axillary dissection 
should replace the Halsted radical mastectomy as the standard of care.(20) With an 
understanding that this recommendation reflected a new theory of breast cancer biology the 
consensus conference went on to recommend that the evaluation of procedures aimed at 
preserving the breast should be vigorously pursued.  
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Table 2.1 Differences between the Halsted Theory and Fisher’s Alternative Hypothesis 
 
Halsted’s Theory 
 
 
Fishers Alternative Hypothesis 
 
Tumors spread in an orderly fashion based on 
mechanical considerations 
There is no orderly pattern of tumor spread 
Tumors spread to lymph nodes via direct 
extension and therefore an “en block” resection 
is required 
Tumor cells travel to lymphatics via 
embolization 
A positive lymph node indicates tumor spread 
and equates to systemic disease 
A positive lymph node is an indicator of a 
host-tumor relationship that permits the 
development of metastasis rather than the 
instigator 
Regional lymph nodes (RLN) are a barrier to 
the passage of tumor cells 
RLN do not serve as a barrier to spread 
RLN are anatomically important RLN are biologically important 
Tumor does not spread hematologically Hematologic spread is an important way that 
breast cancer disseminates 
Cancer is autonomous of the patient Complex host-tumor inter-relationships affect 
every aspect of the disease 
Operable breast cancer is a local regional 
disease 
Even operable breast cancer is a systemic 
disease 
The extent of surgery is the most important 
factor determining patient outcome 
Variations in local regional treatment are 
unlikely to substantially affect survival 
No consideration was given to multicentricity Multicentric foci of occult tumor are not 
necessarily a precursor of clinically overt 
cancer 
 
Fisher’s seminal publication of the NSABP-06 clinical trial in the New England Journal of 
Medicine in 1985 was the first of 10 long term randomized controlled trials, demonstrating that 
breast conserving surgery (BCS) has equal survival compared with a modified radical 
mastectomy. (19, 21-30)  In his study patients with T1or T2, N0 or N1, M0 breast cancers 4 cm. 
or less were randomized into one of three treatment arms: total mastectomy, lumpectomy or 
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lumpectomy followed by breast irradiation. In the NSABP-06 trials lumpectomy was defined as 
removal of “only sufficient tissue to ensure that the margins of resection were free of tumor.”(19) 
While it is now generally accepted that breast conserving surgery is equivalent to modified 
radical mastectomy in terms of survival it was clear from Fisher’s first publication that it comes 
at the cost of increased local regional recurrence.(18, 26, 31-35) In his original report a Cox 
regression model indicated only three covariates that predicted tumor recurrence—treatment with 
radiation post operatively, tumors with poor histology and tumors greater than 2 cm. in size. 
Because of the way that various authors have dealt with the concept of local recurrence it is 
difficult to compare the incidence of local recurrence from one publication to another. Some 
authors include nodal recurrence in their definition while the majority restricts their definition to 
disease in the breast alone. Still others make a distinction between true recurrences and new 
primary disease in the breast. This will be discussed in more detail later in this literature review. 
In the NSABP-06 trial they only considered a recurrence to be a local recurrence if it was the 
first presentation of recurrent disease. In other words if a given patient developed metastatic 
disease first and then developed a recurrence in the breast it was not considered a local 
recurrence. Depending on the publication local recurrence is considered at any of a number of 
time periods with five, ten, fifteen and twenty year follow-up being common end points. Clearly 
the length of follow-up will influence the rate of local recurrence but this is often forgotten in the 
subsequent discussion. With that as background the published local recurrence rates for BCT 
range from a low of 3-14.3% at five years.(21, 36-44)  
A substantial body of literature followed Fisher’s 1985 study looking to understand what, if 
any, factors might predict for local recurrence with a view to either modify the variable itself in 
such a way as to improve the rate of local recurrence or to modify the selection of patients who 
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are candidates for BCS. The initial publications consisted of small numbers of cases with short 
follow-up and weak statistical analysis. With time, studies examining larger data sets with longer 
follow-up and using multiple variable regression techniques emerged. Initially the variables 
examined were limited to the concepts already in the literature. These variables were age, tumor 
grade, tumor size, histological type, the presence of extensive duct carcinoma in situ (DCIS) 
lymph node status, the use of radiation boost to the tumor bed, lymphovascular invasion, 
estrogen receptor status, and the presence or absence of multifocality. The possibility of a narrow 
but negative surgical resection margin being a variable that might negatively affect local 
recurrence had not yet surfaced in the collective thought of the research community, hence it was 
not a variable that was examined early on.  
In the mid to late 1980’s several articles were published that examined surgical specimens 
that were re-excised after an initial lumpectomy looking for the incidence of residual carcinoma 
in the re-excised specimen. Overall these studies showed that there was a higher rate of residual 
carcinoma in re-excised positive or narrow margin lumpectomies compared with lumpectomies 
in which the initial surgical resection margin was greater than 2 mm.  
Subsequently a number of studies including margin status as one of the variables to be 
examined in the multiple variable analysis were conducted. Originally these studies only 
considered margin positivity. Starting in 1987 until as late as 2009 articles including positive 
margin status were published. By early 2000 19 articles had been published showing a strong 
association between a positive surgical resection margin and local recurrence. Even though a 
further 9 articles confirming this association have been published since 2000 the consensus 
opinion by then was that there was adequate evidence to support re-excision of lumpectomies in 
which the surgical resection margin was positive.  
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The first article that considered the possibility of a narrow surgical resection margin being 
associated with local recurrence was an article by R.D. Pezner et al. entitled “to boost or not to 
boost: decreasing radiation therapy in conservative breast cancer treatment when ‘inked’ tumor 
resection margins are pathologically free of cancer.”(45) Since then twenty-one other 
publications have specifically considered narrow or close resection margins and their effect on 
local recurrence in the ipsilateral breast following BCT. These publications will be examined in 
some detail subsequently.  
Like the issue of narrow margins the potential role that systemic adjuvant therapy might play 
on local recurrence in BCT was not initially examined. With time more and more early stage 
women began to receive systemic adjuvant therapy (either chemotherapy or hormonal therapy) 
and it was only then that the potential role in decreasing local recurrence became evident. The 
first publication considering this was an article by Fisher in 1989.  
Most recently the molecular work with DNA microarray analysis has begun to make its way 
into the literature as a potential predictor of local recurrence and this will also be examined in 
some detail. 
2.3.2 Definition of Local Recurrence 
Unfortunately there is no consistent definition for local recurrence used in the literature, 
making comparison of studies somewhat challenging. Depending on the publication, local 
recurrence has included nodal recurrence, skin recurrence, all recurrences in the ipsilateral breast 
or selective ipsilateral breast recurrences.  
Given that the difference between mastectomy and breast conserving surgery is the extent of 
surgery in the breast, most authors have not included axillary nodal recurrence in their definition 
of local recurrence. There is no evidence that could be found to support the concept that nodal 
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recurrence is increased in breast conserving surgery supporting the majority of authors who have 
not included it in their definition.  
A recurrence of malignancy in the ipsilateral breast could, in theory, be due to recurrence of 
residual disease or a new primary malignancy, a concept first articulated by Veronesi.(46) The 
literature addressing this question suggests that there is likely a difference in the biological 
significance of these two theoretical events and an attempt to distinguish between them would be 
reasonable for that reason alone.(46-49) According to the hypothesis advance by Veronesi, true 
recurrences are cases consistent with regrowth of malignant cells not removed by surgery and not 
killed by adjuvant radiotherapy. New primary tumors however are new malignancies arising 
from residual breast epithelium. Subsequent literature suggests that this concept is likely true 
with new primary malignancies having a better prognosis than true recurrences.  While both 
types of recurrence are a consideration with BCT only true recurrences would be affected by the 
extent of resection of the primary tumor assuming that the incidence of new primary tumors is 
the same whether the person had a small amount of breast tissue removed or a larger one. 
Komoike et al. used location of the primary and secondary tumor, initial surgical resection 
margin and other pathology to distinguish true recurrences from new primaries while others used 
location histology and DNA flow cytometry or just location and histology.(50) Abd-Alla et al. 
provides us with a useful clinical definition in which an ipsilateral breast recurrence was 
considered a true recurrence if it was located within 3 cm of the primary tumor bed and had a 
histological subtype consistent with the primary tumor.(47)  
While the current methods described to differentiate a true recurrence from a new primary 
tumor are useful when the local recurrence is in a separate quadrant of the breast or of a different 
histology tumor heterogeneity makes it extremely difficult to distinguish the two when the local 
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recurrence occurs in the same general location in the breast as the primary malignancy and is of 
the same histology. It is likely that genetic markers will aid in distinguishing true recurrence 
from new primaries in the future.  
2.3.3 Definition of a Narrow Surgical Resection Margin 
There is a lack of consistency in the literature around what is called a narrow surgical 
resection margin adding a degree of challenge to the comparison of publications. While the most 
common definition is less than or equal to two millimeters some authors have used a one 
millimeter margin and others have used three millimeters or even more.  
2.3.4. Re-excision Studies 
The initial re-excision studies conducted by Solin et al., Frazier et al., and Schnitt et al. will be 
examined closely as they seem to have been significant in informing the narrow or close margin 
debate early on.  
In all of these studies the authors reported the rates of residual carcinoma in re-excision or 
mastectomy specimens. In Solin’s series they examined 185 patients who underwent an 
excisional biopsy. They found that 51% of the re-excised specimens had residual carcinoma and 
that a positive initial resection margin carried with it the highest likelihood of residual disease 
(60%). They concluded however “when inked margins were negative re-excision is not 
recommended” as the residual carcinoma rate in that group was not high.(51) In Frazier’s study 
they examined both re-excision specimens and mastectomy specimens. If the initial biopsy was 
positive the likelihood of residual carcinoma was 21/40 (52.5%), if it was close it was 
9/28(32.1%) and if it was negative it was 5/19 (26.3%).(52) The Schnitt study of 71 re-excised 
specimens indicated a higher residual carcinoma rate if there was an extensive amount of DCIS 
in the initial lumpectomy.(53)  
 15 
The issue of residual tumor in re-excision specimens continues to garner interest. In 
Skripenova’s 2010 publication he reviewed lumpectomy specimens that had a subsequent re-
excision and found a higher rate of residual carcinoma in specimens that had an initial positive 
margin (44%), versus a less than 1 mm. margin (25%) versus a margin of 1-2 mm (28%) versus a 
margin greater than 2 mm (16%).(54) In 2006 a similar study conducted by Scopa et al. reviewed 
201 lumpectomies that were re-excised and found a 63% residual carcinoma rate in those whose 
initial margin was positive, a 30% residual carcinoma rate if the original resection was 0-1mm, 
and a 21% residual rate if the initial margin was greater than 1mm.(55) Sabel et al., Cellini et al., 
Gwin et al., and Swanson all found no significant difference between positive and narrow margin 
re-excisions.(56-59)  
In all of these studies the number of narrow margin specimens was limited and in all of the 
studies the cohort was restricted to specimens in which a re-excision was conducted for clinical 
reasons. As such we do not know what the rate of residual carcinoma would have been in re-
excised wider margin lumpectomies and a real comparison cannot be made. In 2007 Kotwall et 
al. conducted a study in which all patients had either a second excision or mastectomy following 
their initial lumpectomy.(60) In his study if the initial lumpectomy showed multiple focally 
positive margins the subsequent re-excision showed residual carcinoma 30% of the time, if it 
was focally positive 22% of the time, if it was less than 1mm the residual rate was 8%, 15% if 
the margin was 1-2mm and 4% if the initial margin was greater than 2 mm. Unfortunately, there 
is no indication in his article whether or not the initial lumpectomy was designed to be definitive 
or not. Given that all initial lumpectomies went on to further surgery it is likely that the initial 
lumpectomy was designed only to be diagnostic in which case one would expect there to be a 
high frequency of residual carcinoma in lumpectomies with positive margins.   
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These re-excision studies led some to conclude that the need for re-excision of tumors with an 
initial narrow margin is self-evident. Presumably this explains why a recent survey of 
oncologists showed that a significant number of them advocated either a 1 or 2 mm surgical 
margin and some as much as a 3 mm margin or greater.(61) That conclusion fails to take into 
account the known effect of adjuvant whole breast radiotherapy. It is accepted that, in the 
absence of radiotherapy, there is a significant (30%) local recurrence rate. Postoperative whole 
breast adjuvant radiotherapy reduces that risk to the now accepted range of approximately 1% 
per year.  The addition of a boost of radiation to the tumor bed further reduces the local 
recurrence risk to about 6% over 10 years.  
More significantly, in BCT the appropriate question to be asked is not how much residual 
disease is present after a lumpectomy but rather what amount of lumpectomy is necessary for the 
residual breast tumor burden to be lowered enough that it is likely to be controlled by adjuvant 
radiotherapy. The question of the amount of residual disease would become pertinent if 
consideration was made to forego radiation therapy in selected cases as is currently being 
discussed by some authors.  
2.3.4 Variables Associated with Local Recurrence 
2.3.4.1 Radiation as a variable 
2.3.4.1.1 Overview 
There is little doubt that post-operative adjuvant radiation decreases local recurrence 
following breast conserving surgery. Breast Conserving Therapy (BCT) in fact refers to a 
lumpectomy with negative surgical resection margins and post-operative whole breast radiation 
therapy. This is currently one of two accepted methods of treating early stage breast cancer, the 
other being a simple mastectomy. In both scenarios some sort of lymph node sampling is still 
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considered important for prognostication and decision making regarding systemic adjuvant 
therapy but not for local control.  
Beginning with Fisher’s NSABP-06 trial that showed a statistically significant difference in 
local relapse between patients who had a lumpectomy only versus a lumpectomy and post-
operative adjuvant irradiation (40% vs. 10% at 8 years) multiple studies have demonstrated the 
significant benefit of post-operative adjuvant radiation therapy.(62-69) Unlike most variables 
associated with BCS the beneficial effects of adjuvant radiation has been studied in six 
randomized prospective trials and subjected to two meta-analysis.(21, 37, 38, 40-42, 70, 71)  
2.3.4.1.2 Radiation Dose 
The “standard” radiation dose ranges from 45-50.4 Gray (Gy) given to the whole breast. A 
number of centers advocate for a “boost” of radiation to the tumor bed anywhere from 16-25 Gy. 
A boost of radiation has been shown to further reduce local recurrence but at a cost of increased 
fibrosis and a poorer cosmetic outcome. The randomized boost vs. no boost EORTC 22881-
10882 trial reported by Bartelink et al. reports a reduction in local recurrence at 10 years from 
10.2% to 6.2% in those patients who had a 16 Gy boost of radiation with an associated increase 
in severe fibrosis of 4.4% vs. 1.6% in the no boost arm.(72) These numbers were statistically 
significant. 
2.3.4.1.3 Radiation timing 
A number of articles have been published exploring the importance of the timing of post-op 
radiation in local recurrence.  
In 2002 Hebert-Croteau et al. reviewed the literature and found conflicting evidence. There 
was only one experimental study, which suggested that a delay to radiation might compromise 
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local control consistent with a few retrospective studies.(73) Other observational studies suggest 
otherwise. 
Subsequently Ampil noted a trend toward more local and systemic failure when breast 
irradiation was initiated more than seven weeks following BCS.(74) Fortin et al., Bese et al. and 
Vujovic et al. also found that delays in post-operative radiotherapy might increase the risk of 
local recurrence.(75-78) Punglia et al. found a continuous relationship between the interval from 
breast conserving surgery to post-operative radiation and local recurrence in older women.(79) 
Benchalal et al., Donato et al and Jobsen et al. all found that it was safe to delay radiation until 
after systemic treatment was complete.(80-82) Meanwhile Cefaro et al. found no impact on 
delayed radiation.(83) 
In summary the role of radiation timing in local recurrence of early stage breast cancer is 
inconclusive. 
2.3.4.2 Age as a variable 
After radiation, young age is the most consistently found variable to be associated with local 
recurrence in BCT.(64, 84-115) Exactly what age is used to define “young” varies from 32 to 50 
with the vast majority of authors using age 35 or 40 as the cut off. Not only is this variable the 
most consistently found association with local recurrence it is the strongest association next to 
radiation therapy.  
Having said that one study looking specifically at the question of age found no 
association.(116) They found instead that other factors, such as positive margin, high grade, 
extensive duct carcinoma in situ (ext. DCIS) and lymphovascular invasion predicted for local 
recurrence better. In fact, in their multiple variable regression model age was not an independent 
predictor at all. Moreover, many of the articles that used multiple variable regression did not find 
age to be an independent predictive variable. 
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2.3.4.3 Positive margin as a variable. 
A positive surgical resection margin has been strongly associated with local recurrence in 
BCS in a large number of studies. It is widely accepted that re-excision of a positive margin 
constitutes the current standard of care.(63, 68, 84, 94, 102, 103, 109, 113, 114, 116-127) 
More recent literature makes a distinction between focally positive and widely positive 
surgical resection margins, with some studies demonstrating no difference in local recurrence 
between focally positive lumpectomies and more widely excised malignancies, especially in the 
setting of a boost of radiation to the tumor bed.  
2.3.4.4 Tumor size as a variable 
Early stage breast cancers include both T1 and T2 tumors. The American Joint Committee on 
Cancer (AJCC) staging manual seventh edition defines T1 tumors as being less than or equal to 2 
cm. in size while T2 tumors are “more than 2 cm. but not more than 5 cm. in greatest 
dimension”. Tumor size greater than 2 cm. was one of three variables associated with local 
recurrence in the NSABP-06 trial (radiation and poor histologic type being the other two). This 
association has been confirmed in several other studies but it remains one of the weaker 
associations.(18, 64, 94, 96, 98, 106, 108, 113, 128)  
2.3.4.5 Extensive duct carcinoma in situ (Ext DCIS) as a variable 
Ext DCIS is defined as being present when 25% or more of the area encompassed by invasive 
tumor and DCIS is DCIS. There has been a fair body of literature addressing the association 
between Ext DCIS and local recurrence.(46, 88, 89, 99, 101, 115, 116, 118, 120, 122, 123, 129, 
130) While many studies did demonstrate an association with extensive DCIS and local 
recurrence the significance of this variable is likely diminished or even eliminated if complete 
pathologic excision can be achieved.  
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2.3.4.6 Lymphovascular invasion as a variable. 
Angiolymphovascular invasion, defined as invasive cancer observed infiltrating 
lymphovascular spaces is one of the stronger variables associated with local recurrence in 
BCT.(89, 101, 103, 108, 109, 111, 116, 131)  
2.3.4.7 Lymph node status as a variable 
Despite a strong association between axillary lymph node status and survival the association 
with local recurrence in BCT, while present, is not as strong or as consistent.(89, 98, 101, 108, 
115, 129, 132) 
2.3.4.8 Estrogen Receptor (ER) status as a variable. 
As is the case with lymph node status the strong association between ER status and survival 
does not seem to translate to local recurrence. There have only been a few studies showing an 
association between ER status and local recurrence in BCS. (89, 101, 111)  
2.3.4.9 Grade as a variable 
Tumor grade has only variably been associated with local recurrence in BCS.(116, 123, 131, 
132)  
2.3.4.10 Systemic adjuvant therapy as a variable 
Systemic adjuvant therapy was not noted to be an association in the earlier literature on BCT 
primarily because during that time only node positive women were receiving system adjuvant 
therapy. Only when more and more node negative women began to receive systemic adjuvant 
therapy was the possibility of this association considered. It is now widely acknowledged that 
there is an association with systemic adjuvant therapy (either hormonal therapy or 
chemotherapy) and decreased local recurrence.(62, 68, 92, 97, 98, 113, 133-136) 
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2.3.4.11 Other histological types as a variable 
The World Health Organization classification of breast carcinoma is as follows: (137) 
1. Carcinoma in situ 
 a. duct carcinoma in situ (DCIS) 
 b. lobular carcinoma in situ (LCIS) 
2. Invasive ductal carcinoma 
 a. microinvasive carcinoma 
 b. invasive duct carcinoma not otherwise specified (NOS) (80%) 
     i. Mixed type carcinoma 
ii. Pleomorphic carcinoma 
iii. Carcinoma with osteoclastic giant cells 
iv. Carcinoma with choriocarcinoma features 
v. Carcinoma with melanotic features 
 c. Invasive lobular carcinoma (10%) 
The histopathologic features of this cancer include small cells with rounded nuclei, 
inconspicuous nucleoli, and scant cytoplasm. This cancer is frequently multifocal, 
multicentric and bilateral.(138-140) 
 d. Tubular carcinoma (2%) 
This is another good prognosis carcinoma compared with infiltrating duct carcinoma. 
Some have suggested that adjuvant radiation could be omitted in these patients because 
of this.(141, 142)  
 e. Invasive cribriform carcinoma 
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 f. Medullary carcinoma (4%)  
This type of carcinoma is frequently seen in BRCA-1 hereditary breast cancer. 
Bilaterality is reported in 20% of cases. It is characterized by a dense lymphoreticular 
infiltrate composed predominately of lymphocytes and plasma cells, large pleomorphic 
nuclei that are poorly differentiated and show active mitosis and a sheet-like growth 
pattern with minimal or absent ductal or alveolar differentiation. Women with this 
cancer have a better 5 year survival rate.  
 g. Mucinous carcinoma and other tumors with abundant mucin (2%) 
i. Mucinous carcinoma 
This tumor typically presents in elderly patients as a bulky tumor. It is defined by 
extracellular pools of mucin, which surround aggregates of low-grade cancer cells. 
This tumor has a better prognosis.(138)  
ii. Cystadenocarcinoma and columnar cell mucinous carcinoma 
iii. Signet ring cell carcinoma 
 h. Neuroendocrine tumors 
i. Solid neuroendocrine carcinoma 
ii. Atypical carcinoid tumor 
iii. Small cell/oat cell carcinoma 
iv. Large cell neuroendocrine carcinoma 
 i. Invasive papillary carcinoma (2%) 
This cancer tends to present later in life and occurs in a disproportionate number of 
nonwhite women. These tumors tend to be small (rarely greater than 3 cm). This 
carcinoma has a better prognosis than infiltrating duct carcinoma.(138) 
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 j. Invasive micropapillary carcinoma 
This cancer, characterized by delicate pseudopapillary structures lacking a 
fibrovascular core and tubuloalveolar structures freely floating in clear, empty spaces 
is quite rare and has a highly aggressive behavior.(143, 144) 
 k. Apocrine Carcinoma 
 l. Metaplastic carcinomas 
i. Pure epithelial metaplastic carcinomas 
Squamous cell carcinoma 
Adenocarcinoma with spindle cell metaplasia 
Mucoepidermoid carcinoma 
ii. Mixed epithelial/mesenchymal metaplastic carcinomas 
 m. Lipid-rich carcinoma 
 n. Secretory carcinoma 
 o. Oncocytic carcinoma 
 p. Adenoid cystic carcinoma 
 q. Acinic cell carcinoma 
 r. Glycogen-rich carcinoma 
 s. Sebaceous carcinoma 
 t. Inflammatory carcinoma: defined clinically as enlarged erythematous breast.  
In Fisher’s NSABP-06 trial tumors of poor histological type were one of the variables 
identified that predicted local recurrence.  
 24 
2.3.4.12 Other variables in the literature.  
Other variables that have been examined include multifocality, menopausal status and a 
number of biomarkers including Bcl-2, Ki-67, c-erbB-2, waf-1and p53 but there are few studies 
that examined these issues.  
2.3.4.13 Narrow margin as a variable. 
2.3.4.13.1 Overview 
Given that this is the variable of primary interest in this thesis all of the papers published in 
the literature to date that have examined the issue of narrow surgical resection margin were 
reviewed. A total of twenty-two publications were identified—four that found a positive 
association and eighteen that did not. Of these twenty-two publications four of them (two 
showing an association and two not) were the same data sets reported upon at different dates.  
2.3.4.13.2 Schnitt SJ et al. The Relationship between Microscopic Margins of Resection and the 
Risk of Local recurrence in Patients with Breast Cancer Treated with Breast Conserving Surgery 
and Radiation Therapy.(118) 
This retrospective study conducted on 181 patients who underwent BCT was published in 
1994. All patients received a higher dose of radiation than is standard (60Gy or higher). A 
positive surgical resection margin was defined as tumor at the inked margin and was further 
divided into focally positive and positive, a close margin was tumor within 1 mm, and a negative 
margin was defined as no tumor within 1 mm of the inked margin. Medium follow up was 86 
months. Local recurrence rates were 21%, 6%, 4% and 0% for positive, focally positive, close 
and negative surgical resection margins respectively. The authors concluded that there was no 
difference in local recurrence rates based on margin of resection.  
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Critique: 
Like many of these studies this study had too small a number of narrow margin cases to 
address the issue it purports to. There were only 25 close margin cases, 48 focally positive cases 
and 38 cases that were more than focally positive cases. They included nodal failure in their local 
recurrence numbers.  
2.3.4.13.3 Gage, I et al. Pathologic Margin Involvement and the Risk of Recurrence in Patients 
Treated with Breast Conserving Therapy(145) 
This retrospective study published in 1996 examines the question of local recurrence in BCS 
with a particular view to clarifying the Ext DCIS issue. Of 1790 women treated with BCT the 
343 with Ext DCIS formed the basis for their study. Surgical resection margins were classified as 
negative if it was greater than 1 mm from the inked margin, close if it was within 1mm and 
positive if there was tumor at the inked margin. The positive margins were further divided into 
focally positive or widely positive. The 5 year ipsilateral breast recurrence rate was 2% for close 
and 3% for negative margins. Table 2.2 looks at their data by Ext DCIS status. The authors 
conclude that focally positive tumors could be treated with BCT 
Table 2.2 Gage study recurrence by Ext DCIS and margin status 
Margin Ext DCIS No Ext DCIS Overall 
Negative 2/14(14%) 1/93(1%) 3/107 (3%) 
Close 0/10(0%) 1/44(2%) 1/54 (2%) 
Focally positive 1/14(7%) 6/65(9%) 7/79 (9%) 
Positive 8/19 (42%) 6/31(19%) 14/50 (28%) 
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Critique: 
This retrospective paper has too few narrow margin cases to make a valuable contribution on  
the question of local recurrence in BCT either for narrow margins or for the question of Ext 
DCIS. 
2.3.4.13.4 Touboul E et al. Local Recurrences and Distant Metastases after Breast Conserving 
Surgery and Radiation Therapy for Early Breast Cancer(99) 
This retrospective study, published in 1999, is a study of 528 patients who underwent BCS. It 
was designed to look for factors predictive of local recurrence. All histological types were 
included. A boost dose of radiation was given in about half of the patients. Margin status was 
classified positive in 13 cases, close (less than or equal to 2 mm) in 21 cases, negative (greater 
than 2mm) in 417 cases and indeterminate in 77 cases. Multivariate analysis showed only four 
factor to contribute to the prediction of local recurrence—young age (less than or equal to 40), 
premenopausal status, bifocality and extensive DCIS.  
Critique: 
The number of close margins was too small to make use of this study to comment on the 
contribution of surgical resection margins on local recurrence in early stage breast cancer. (21) 
2.3.4.13.5 Freedman G et al. Patients with early stage invasive cancer with close or positive 
margins treated with conservative surgery and radiation have an increased risk of breast 
recurrence that is delayed by adjuvant systemic therapy.(146) 
This retrospective review of 1,262 stage I and II breast cancer patients seeks to clarify the 
width of the resection margin that minimizes the risk of local recurrence in BCT. Published in 
1999 the study had a median follow-up is 6.3 years and a range of 0.1-15.6 years. Margin status 
was classified as negative, close (less than or equal to 2mm), or positive. 59% had a re-excision. 
There were 968 negative margin, 142 narrow margin and 152 positive margin cases at the time 
of the initial excision. It is unclear how many patients remained in these categories following re-
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excision. At 5 years follow up the local recurrence rates between the groups was not statistically 
different but by 10 years there was a statistically significant difference between the negative 
group (7%) and either the narrow margin group (14%) or the positive margin group (12%).  
Critique: 
There are several methodological problems with this study that make it difficult to interpret. 
Like so many studies examining the issue of narrow margins in local recurrence of early stage 
breast cancer treated with BCS the numbers are small. They do not tell us how many narrow 
margin patients there were in this group following re-excision but we do know that the initial 
size was 142 and that 43% of that group had a re-excision. It is assumed that the size of the 
remaining group was around 81 (142 x .57). They did not use multiple variable regression 
techniques so none of the other potential variables were considered in the analysis, including the 
fact that the narrow margin group had a significant greater number of lymph nodes positive than 
the wider margin group. Finally, the difference didn’t appear until 10 years. There would have 
been very few patients remaining at that point as the follow-up median was only 6.3 years with a 
range of 0.1-15.6. For all of the above reasons this study, while adding to the literature, can not 
stand alone in informing the debate around narrow margins and local recurrence in early stage 
breast cancer treated with BCS. In fact, the methodological concerns make one wary of drawing 
any strong conclusions.   
2.3.4.13.6 Peterson ME et al Outcomes in breast cancer patients relative to margin status after 
treatment with breast conserving surgery and radiation therapy: the University of Pennsylvania 
experience.(147) 
This retrospective study of 1,021 early stage breast cancer patients treated with BCT was 
published in 1999. It was designed to look at local recurrence in relation to margin status. The 
authors divided the patients into four margin categories based on the final margin status. There 
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were 518 negative margin patients, 124 focally positive margin patients, 96 patients with a close 
margin (less than or equal to 2 mm), and 283 patients with unknown margins. The local 
recurrence rates at 8 years were 8% vs. 10% vs. 17% vs. 16% for negative, focally positive, close 
and unknown margins respectively. This was not statistically significant. The authors concluded 
that close margins did not require re-excision.  
Critique: 
This rather straightforward retrospective study is still underpowered but does add to the 
debate regarding narrow margins in BCT in so much as it addresses the topic without a lot of 
extraneous information and can be compared with other studies.  
2.3.4.13.7 Park CC. et al. Outcome at 8 Years After Breast Conserving Surgery and Radiation 
Therapy for Invasive Brest Cancer: Influence of Marin Status and Systemic Therapy on Local 
Recurrence(148) 
This is a retrospective review of 533 patients that was designed specifically to assess the 
influence of margin status on local recurrence. Published in 2000, it found no difference between 
patients with a negative or close (less than 1 mm) surgical resection margin (both 7%). Focally 
positive and extensively positive resection margins had a 14 and 27% local recurrence rate 
respectively. All cases were pathologically reviewed. Local recurrence included all ipsilateral 
breast and skin recurrences.  
Critique: 
While the number of cases (94 close margin, 204 negative, 66 extremely positive and 122 
focally positive) was more than most studies it is still under powered. The definition of local 
recurrence includes both true recurrences as well as new primaries.  
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2.3.4.14.8 Perez C. Conservation therapy in T1-T2 breast cancer: Past, current issues and future 
challenges and opportunities(97) 
This retrospective study published in 2003 examined local recurrence in BCT in relation to 
both tumor size and margin status. They found no statistical difference between the groups in 
local recurrence. Table 2.3 shows their data. They had a total of 1037 patients. A close margin 
was defined as less than or equal to 3mm. 
Critique: 
 This study has too few close margins for any strong conclusion but showed no statistical 
difference in local recurrence between the margin groupings. 
Table 2.3 Data from Perez regarding local recurrence and margin status. 
Size Positive Close Negative Unknown 
T1 1/30 (3.3%) 0/40 (0%) 16/438 (3.6%) 18/196 (9%) 
T2 2/16 (12.5) 1/16 (6%) 7/105 (6.6%) 4/68 (5.9%) 
Total 3/46 (6.5%) 1/56 (1.8%) 23/543 (4.2%) 22/264 (8.3%) 
 
2.3.4.13.9 Fredriksson et al. Risk factors for local recurrence after breast conserving 
surgery(149) 
This article, published in 2003, was a case-control study. They used a cohort of 7502 women 
who underwent BCS for either invasive carcinoma or insitu carcinoma. 491 cases of local 
recurrence were matched with 1098 controls from the cohort. Local recurrence was defined as 
any histology in the recurrent breast including skin. Axillary recurrences were not considered 
local recurrences. All pathology slides were reviewed. There were four margin groups. A 
negative margin was defined a greater than or equal to 1 mm, a positive margin as less than 
1mm, a doubtful margin as “close but not measured” and an unknown group that was not further 
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defined. Multivariate conditional logistic regression analysis showed that age less than 40, 
radiotherapy, adjuvant hormonal therapy, tumor multicentricity and unclear or unknown surgical 
resection margins were predictive of local recurrence.  
Critique: 
It is very unfortunate that this otherwise quite well constructed retrospective case-control 
study does not shed much light on the question of the significance of narrow resection margins in 
predicting local recurrence. Especially given that all of the pathology slides were reviewed it is 
disappointing that we do not know what either an unclear or an unknown surgical resection 
margin means. Either could be a positive margin, a narrow margin or a combination of both. This 
reality leaves this study uninterpretable with regards to margin status. 
2.3.4.13.10 Smitt, MC et al. Predictors of re-excision finding and recurrence after breast 
conservation.(150) 
This 2003 retrospective review is an update of a previous publication. 535 patients who 
underwent BCT followed for a mean time period of 6 years were examined for prognostic 
factors. Margin status was classified as negative, close (less than or equal to 2 mm), positive or 
indeterminate. Margin status was the most important predictor of local recurrence in their cohort. 
The results are found in table 2.4. 
Table 2.4 Smitt data for local recurrence rates by final margin status  
Margin Patient number Recurrence in % 
6 year actuarial 
% Crude 
Recurrence 
Negative 342 3 3 
Close 55 22 13 
Positive 28 17 18 
Indeterminate 110 15 17 
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Critique: 
This retrospective study shows margin status, including narrow margin, to be a significant 
predictor of local recurrence in BCT for early stage breast cancer. The small number of close and 
positive margin cases is a concern. With the multitude of other variables thought to have an 
influence on local recurrence one would need to see these results reported on a more consistent 
basis to draw cause and effect conclusions. 
2.3.4.13.11 Chism DB et al. Re-excision of margins before breast radiation-diagnostic or 
therapeutic?(151) 
This retrospective study, published in 2006, examined only patients with either a close (less 
than or equal to 2mm) or positive initial surgical resection margin. The 1,044 patients were 
divided into three groups: 
1. no further excision (n=199) 
2. re-excision with no residual tumor found (n=546) 
3. re-excision with residual tumor found (n=299) 
There was no statistical difference in local recurrence between the three groups over a 10 year 
period. 
Critique: 
This observational study, which has a reasonable number of narrow margin cases, would 
suggest that BCS with a narrow resection margin can result in a low local recurrence rate but the 
lack of comparison to a wider resection margin limits its usefulness. 
2.3.4.13.12 Kunos, C et al. Breast Conservation Surgery Achieving >/= 2mm Tumor-Free 
Margins Results in Decreased Local-Regional Recurrence Rates.(152) 
This is a retrospective review of 341 early stage breast cancer patients who were followed for 
a median of 56 months (range of 10-105 months).  Published in 2006 the purpose of the study 
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was to examine the role of margin status on loco-regional recurrence. Multivariate analysis 
showed negative ER status, close surgical resection margin and the presence of angiolymphatic 
invasion to be predictive of local recurrence.  
A narrow margin was defined as less than or equal to 2mm. All patients who had an initial 
narrow margin were re-resected up to two times unless it was deemed that doing so would affect 
cosmesis. Histologic confirmation of margin status was possible in only 86% of cases. More of 
the narrow margin group had extDCIS. 
The local recurrence rate was 4/22 (1.8%) of the negative group and 10/119 (8.4%) of the 
narrow margin group. This was statistically significant at p=.007.  
Critique: 
While this retrospective study does show a statistically significant difference in local 
recurrence rate between the narrow and wide margin groups there are some methodological 
concerns other than small sample size that diminish the strength of the study. Local recurrence 
was defined as any of lymph node recurrence together with both true recurrences and new 
primaries. There is no evidence in the literature that BCS impacts nodal recurrence in any way. 
The narrow margin group (which is the smaller of the two) had twice as many nodal recurrences 
than the wide margin group. Furthermore, by having a policy wherein all patients with a narrow 
surgical resection margin underwent a re-excision (or two) unless it was deemed to negatively 
affect the cosmetic result they have inadvertently created a selection bias that would select larger 
tumors into the narrow margin group as those which could be easily be re-excised would have 
had a re-excision placing them into the wider margin group. Because of these concerns this study 
does not contribute significantly to the debate on the significance of narrow resection margins on 
local recurrence in early stage breast cancer treated with BCT. 
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2.3.4.13.13 Bollet, MA et al. Age remains the first prognostic factor for loco-regional breast 
cancer recurrence in young (<40 years) women treated with breast conserving surgery first.(95) 
This is a retrospective study published in 2007 that looks at the role of a narrow surgical 
resection margin in younger aged women. Young age group was focused upon because of the 
association between young age and local recurrence.  Two hundred and nine patients were 
divided into two margin categories, greater than 3 mm or less than 3 mm. They found that 
surgical resection margin did not predict for local recurrence.  
Critique: 
This study was underpowered to resolve the problem with only 209 cases, in total of which 
20% or 42 had a close resection margin.  
2.3.4.13.14 Vordermark, D et al. Local control in 118 consecutive high-risk breast cancer 
patients treated with breast conserving therapy.(153) 
In this 2007 retrospective review of 118 patients who had close or positive surgical resection 
margins over a 5 year period the authors conclude that among patients with close or positive 
margins older patients achieved high local control rates. They noted that younger patients and 
those who received adjuvant chemotherapy were at increased risk of local recurrence.  A close 
margin was defined as less than or equal to 4mm. There was no statistical difference in local 
recurrence between the various margin groupings.  
Critique: 
This retrospective study does not have a wider margin arm and it is significantly 
underpowered. Their local recurrence rate of 95.5% in 5 years for the narrow margin group is 
acceptable compared with other studies but their definition of narrow margin (less than or equal 
to 4 mm) is so different from the rest of the literature that it is impossible to make use of this 
information. 
 34 
2.3.4.13.15 Hardy K et al. The Impact of Margin Status on Local Recurrence following Breast 
Conserving Therapy for Invasive Carcinoma in Manitoba.(154) 
This retrospective case control study published in 2008 was designed to shed light specifically 
on the issue of the contribution of narrow surgical resection margins to local recurrence in early 
stage breast cancer local recurrence. His group examined all stage I and II breast cancers treated 
with breast conserving therapy between 1995 and 2004 at the Manitoba Cancer Center.  
In a cohort of 3,017 patients treated with BCT in Manitoba 50 cases of local recurrence were 
matched with 150 controls from the same cohort. These cases were assessed for surgical 
resection margin and were classified as positive, less than 1mm, less than or equal to 2mm, 
greater than 2mm, negative, no residual on re-excision or unknown. The mean follow-up was 60 
months. They concluded that, “no clear benefit to wider histologically negative margins is 
demonstrated”.   
Critique: 
Overall this was a well-conducted retrospective case control study that has some limitations 
worthy of mention. The sample size calculation showed a need for almost three times the 
caseload as they had. All histologies were included and pathologic review was not used. While it 
might be reasonable to assume a measured margin to be valid the statement that, “based on 
informal discussion with local pathologists a report of ‘negative NOS’ margins was typically 
used when margins were greater than 2 mm” is not likely a reasonable assumption to make 
without at least some sort of review to confirm its validity. They identified local recurrences by a 
couple of different search strategies within the database that was available to them rather than 
reviewing all of the charts to determine if there was a local recurrence or not. Only cases deemed 
to be a local recurrence by the above-mentioned process were reviewed. There was no 
consideration given to other variables known or thought to affect local recurrence.  
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2.3.4.13.16 Jones, HA et al. Impact of Pathological Characteristics on Local Relapse After 
Breast Conserving Therapy: A Subgroup Analysis of the EORTC Boost Versus No Boost 
Trial(155) 
This prospective study published in 2009 is a sub-group analysis of the Early Breast Cancer 
Trialists Collaborative Group (EORTC) Boost Versus No Boost Trial. The main objective of that 
trial, which accrued 5,569 patients between 1989 and 1996, was to assess the value of a boost of 
radiation in early-stage breast cancer patients treated with BCT. Margin status was examined in 
all 1,616 enrolled patients with clinical stage I and II breast cancer for this sub-group analysis. 
Margin status was defined as positive if invasive or DCIS was seen at the inked resection 
margin, close if the margin was less than or equal to 2mm, and negative if it was greater than 2 
mm. Statistical analysis was with both a univariate and multivariate analysis using Cox 
proportional hazard models. Local failure was defined as disease recurrence in the treated breast. 
There were 51 patients with a positive margin, 306 with a close margin and 1,137 with a 
negative margin. All pathology slides were centrally reviewed.  The 10 year cumulative risk of 
local breast cancer relapse as a first event was not significantly influenced if the margin was 
scored negative, close or positive. They did find young age and high grade to be important risk 
factors for local recurrence.  
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Critique: 
This prospective recently performed study is adequately powered and finds no difference in 
local recurrence based on margin status. Despite the concern that it is a subset of a larger 
prospective study the information provided by this study should significantly inform the debate 
around surgical resection margins.  
2.3.4.13.17 Perez CA Breast conservation therapy in patients with state T!-T2 breast cancer: 
current challenges and opportunities(156) 
This 2010 publication examines a cohort of 1521 patients treated with BCT examining tumor 
size and margin status in women under the age of 40. They have a ten year follow up. Table 2.5 
shows their data 
Table 2.5 Data from Perez regarding local recurrence and margin status in young women 
Tumor size Negative Close or positive 
T1 9% 12% 
T2 12% 22% 
 
Critique: 
This is a follow up from their earlier study. There is still no statistical difference in local 
recurrence between narrow or positive margins (lumped together in this study) and negative 
surgical resection margins 
2.3.4.13.18 Goldstein NS Factors Associated with Ipsilateral Brest Failure and Distant 
Metastases in Patients with Invasive Breast Carcinoma Treated with Breast Conserving Therapy. 
A Clinico-pathologic Study of 607 Neoplasms From 583 Patients.(157) 
This 2003 publication contains the most extensive pathologic examination of BCS specimens 
found in the literature. The authors extensively examined slides from 607 consecutive breast 
carcinomas treated with BCS to see if they could find anything that predicted local recurrence. 
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All patients with an initial lumpectomy deemed “inadequate” were re-excised as a matter of 
institutional policy. Recurrence was defined as an ipsilateral breast recurrence. In their series 
they had 231 narrow margin cases. They created a 5 tiered composite factor of margin distance 
and amount of carcinoma near the margin such that their close margin group was subdivided into 
three (close with a least amount of tumor, close with an intermediate amount of tumor and close 
with the greatest amount of tumor). There were 101, 87 and 43 patients in each of these narrow 
margin sub-groups. They also subdivided the narrow margins into two groups according to 
margin (0.1-1.0 mm and 1.1-2.0 mm). Their data is shown in tables 2.6 and 2.7. They found no 
difference in local recurrence between near and negative margins but a statistically significant 
increase in local recurrence in patients who had a positive margin. They also found that the 
amount of carcinoma in near resection margins predicted local recurrence (more so than just a 
narrow margin).  
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Table 2.6 Goldstein data local recurrence as a function of final margin status 
Final Margin Status Number of 
cases 
5 year local 
recurrence rate 
12 year local recurrence rate 
Unknown 5 10% 2/5 (40%) 
Positive 38 12% 9/38 (31%) 
Close--total 231 2% 25/231 (12%) 
Close 0.1-1.0 94 1% 14% 
Close 1.1-2 45 0% 6% 
Negative--total 333 3/330 (1%) 30/333 (9%) 
Negative 2.1-3.0 mm 59 2% 15% 
Negative 3.1-5 mm 43 5% 13% 
Negative 5.1-10 mm 90 1% 13% 
Negative >10 mm 52 0% 5% 
Table 2.7 Goldstein data local recurrence considering amount of carcinoma in narrow margin 
cases 
Amount of carcinoma 
near the margin 
Number of cases 5 year local 
recurrence rate 
12 year local 
recurrence rate 
Least 101 1% 6% 
Intermediate 87 3% 18% 
Greatest 43 6% 24% 
 
Critique: 
This series examines the issue of local recurrence in narrow margin lumpectomy used in BCT 
from the perspective of the amount of residual tumor at the closest inked margin. The results 
suggest a kind of dose response curve with the rate of local recurrence increasing with increasing 
amounts of tumor adjacent to the narrow margin. It is interesting to see that margin status itself 
made no difference to local recurrence rates in this series. It would have been of value to see if 
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the volume of tumor at the closest resection margin of the negative lumpectomy specimens 
correlated in any way with local recurrence but that was not done. 
2.3.4.13.19 Karasawa, K et al. Treatment Outcome of Breast Conserving Therapy in Patients 
with Positive or Close Resection Margins: Japanese Multi Institute Survey for Radiation dose 
Effect.(96)  
This 2005 publication examined a database of 971 women who had a surgical resection 
margin less than 5 mm. Of this cohort 941 had adequate information and were included in the 
study. The patients were divided into three groups—positive, narrow (less than or equal to 2 
mm) or greater than 2 mm. Local recurrence was defined as an ipsilateral breast recurrence. 
Their data is presented in Table 2.8. There was no statistically significant difference in local 
recurrence between the three groups. The radiation dose was less than 60 Gy in 252/941(27%) of 
the patients, 60 Gy in 456/941(48%) patients and more than 60 Gy in 233/941(25%) patients. 
Critique: 
This retrospective series has the largest number of narrow margin patients in the literature. 
The authors show no difference in local recurrence rates out to 10 years. A significant number of 
their patients had a boost of radiation. Unfortunately this study did not conduct any multivariable 
analysis. This publication offers a useful contribution to the literature concerning local 
recurrence following a narrow surgical margin because of the significant number of narrow 
margins cases. 
Table 2.8 Karasawa data regarding local recurrence and surgical resection margin 
Margin Number 5 year local recurrence rate 
10 year local 
recurrence rate 
Positive 358 4.9% 14.1% 
Narrow  326 3.2% 9% 
> 2mm 256 4.8% 13% 
 40 
 
2.3.4.13.20 Wazer DE et al. Factors Determining outcome for Breast conserving Irradiation with 
Margin-Directed Dose Escalation to the Tumor Bed(158) 
This paper, published in 1998, studied 509 women treated with BCT with special attention 
paid to a radiation dose escalation that was used at the authors’ institution. Institutional policy 
was that all patients who had a narrow or positive margin on the initial resection were re-excised 
if possible. A narrow margin was defined as less than or equal to 2 mm. Their cohort of 509 
included 105 positive margin patients and 99 narrow margin patients. Univariate analysis 
showed no statistical difference in local recurrence between narrow margin resections and wider 
margin resections. Positive surgical resections were associated with an increased local 
recurrence. The authors concluded that their dose escalation formula provided an exceptionally 
low risk of early local recurrence. 
Critique: 
This paper did not demonstrate any increase in local recurrence in women who had a narrow 
surgical resection margin. The dose escalation formula used by the authors makes it hard to 
know how to compare this study to others in the literature. 
2.3.4.13.21 Smitt, MC et al. The Importance of the Lumpectomy Surgical Margin Status in Long 
Term Results of Breast Conservation.(117) 
This 1995 publication divided patients treated with BCT into groups based on margin status. 
A close margin was defined as less than or equal to 2 mm. from the margin. The margin groups 
were positive, close, negative and indeterminate. Their 5 and 10 year local recurrence rates are 
shown in table 2.9. Their definition of local recurrence included all ipsilateral breast and skin 
recurrences. It was unclear if they included nodal recurrences or not. They concluded that “re-
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excision appears to convey a local control benefit for those patients with close, indeterminate, or 
positive initial margins, when final margins are attained”.  
Table 2.9 Smitt data 
Final margin status (n) 5 year local control (%) 10 year local control (%) 
Negative (157) 98 98 
Close (17) 84 82 
Indeterminate (105) 91  
Focally positive (10) 100  
Diffusely positive (14) 91  
 
Critique: 
There were only a very small number of close surgical resection margins (17 of 303 cases). 
Unfortunately, they combined the 17 close margin patients with the 105 indeterminate margin 
patients and the 24 positive margin patients and compared that group with the negative margin 
group in their analysis rendering the conclusion they made invalid.  
2.3.4.13.22 Pittinger, TP et al. Importance of margin status in outcome of breast conserving 
surgery for carcinoma.(159) 
This retrospective study published in 1994 examined 211 women treated with BCT with a 
view to determine the risk of local recurrence as a function of margin status. In their study a 
close margin was considered to be less than or equal to 3 mm. They divided the 211 women into 
four margin groups, negative, close, positive and unknown. Their data is presented in table 2.10. 
They concluded, “although one fourth of patients with close margins have residual tumor, 
recurrence rates are similar to those with negative margins”.  
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Table 2.10 Pittinger data 
 Negative Close Positive Unknown Total 
Final margin 122 35 4 22 183 
Local recurrence (%) 4 (3) 1(3) 1 (25) 2(9) 8(4) 
 
Critique: 
This retrospective study has a very small number of close margin patients making their 
conclusion difficult to accept as definitive.(35) 
2.3.4.13.23 Solin, LJ The significance of the pathology margins of the tumor excision on the 
outcome of patients treated with definitive irradiation for early stage breast cancer. (160) 
This retrospective study published in 1991 examined 697 women treated with BCT in early 
stage breast cancer. These cases were divided into four groups based on the final pathology 
margin. A negative margin was considered to be one that was greater than 2mm, and a close 
margin was less than or equal to 2 mm. The two other groupings were unknown and positive. 
There was no statistically significant difference in local recurrence amongst the various groups. 
There were 257 negative margin patients, 37 close margin patients, 57 focally positive margin 
patients and 346 unknown margin patients. Their conclusion was that “selected patients with 
focally positive or close microscopic pathology margins can be adequately treated with definitive 
breast irradiation”.  
Critique: 
The small number of narrow margin cases and the large number of unknown margin cases 
make it difficult to consider this study to be one that significantly contributes to the debate of 
narrow margin and local recurrence in early stage breast cancer treated with BCT.  
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 2.3.5 Significance of Re-excision 
2.3.5.1 Overview 
Re-excision of narrow margins would not be much of an issue if there were not negative 
implications of performing further surgery.(161) Delays incurred as result of a second operation, 
financial cost, increased risk of wound infection, decreased patient satisfaction with the cosmetic 
result, and increased anxiety are consequences of re-excision and should be avoided if possible. 
2.3.5.2 Financial cost 
Every operation has a dollar cost associated with it. Even though the majority of 
lumpectomies or segmental resections in Canada are performed on a day surgery basis the cost of 
re-excisions performed for BCT can be significant. In some publications the standard of care was 
to perform up to 2 additional re-excisions in an attempt to gain a surgical resection margin 
greater than 2 mm. Upwards of 50% of patients are submitted to re-excision because of either 
narrow or positive initial lumpectomy resection margin. In a recent series published in 2009 
Kouzminova et al. reported results from their institution where the policy was for all patients 
with a positive or narrow surgical resection margin to undergo re-excision or mastectomy. After 
the first resection 57 (13%) were found to have a narrow surgical resection margin. Of these 69% 
required a second operation to gain a negative margin and 8.6% of these required a third 
operation to clear the margins.(162) With such a policy they would therefore have performed 24 
re-excisions for narrow margins for every 100 lumpectomies in order to obtain the negative 
margins they were looking for.  Based on their data 185 re-excisions would be required for every 
100 narrow margin lumpectomies to obtain clear margins. Therefore we would anticipate 144 re-
excisions annually in Saskatchewan, extrapolating from the database provided for the study done 
for this thesis, which showed about 600 lumpectomies being performed for breast cancer in 
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Saskatchewan each year. If one further assumes a cost of around $2,0001 to perform a re-
excision, in Saskatchewan alone the economic burden of that practice would be in the 
neighborhood of $288,000 annually.  
2.3.5.3 Local recurrence risk 
The literature examining the issue of whether or not re-excision affects local recurrence in 
BCT is not consistent. Menes et al. suggested that the risk of local recurrence following BCS is 
negatively impacted by the need to perform re-excision.(163) O’Sullivan et al. on the other hand 
found the opposite in their study. (164) 
2.3.5.4 Significance of delay to adjuvant therapy 
 It is self-evident that re-excision would result in a delay in the patient receiving adjuvant 
therapy. In Saskatoon the time from an initial diagnostic biopsy until a definitive biopsy 
performed is 28 days. The issues causing that delay are the production of the surgical pathology 
report and the time to get the patient to the operating room. While that data refers to the time 
from diagnostic biopsy to definitive surgery it is only reasonable to assume that a similar delay 
would be encountered with each re-excision as the exact same issues are at play. Re-excision of a 
lumpectomy is associated with an increase in wound infection, which would potentially delay the 
start of adjuvant therapy further.  A third excision would delay treatment even further. 
Depending on the amount of delay there could be potential negative repercussions for the 
individual patient. Delays in receiving radiation are thought to increase the likelihood of local 
recurrence as noted in the section above and delay in commencing adjuvant chemotherapy may 
also be associated with increased local recurrence. (74, 120)    
                                                 
1 Operating room and Pathology cost from the Saskatoon Health Region, physician costs from 
the Saskatchewan Health payment schedule  
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2.3.5.5 Psychological impact 
Several studies have demonstrated increased psychological distress associated with local 
recurrence even though there is a greater patient satisfaction with having BCS in the first place.  
Saskatchewan’s Health Quality Council surveyed women who were diagnosed with breast 
cancer in 2003 and 2004 about their care experiences.(165) Half (51%) of the 716 women who 
responded to the survey said they experienced unnecessary anxiety during at least one part of 
their care. Women felt most anxious during diagnosis and treatment and least anxious during the 
surgery phase. In addition, nearly half (47%) of women reported feeling out of control during at 
least one phase of their cancer care. The longest time delay (typically 62 days) occurred between 
surgery and the start of adjuvant therapy.  
The volume of tissue removed with re-excision surgery is more than if only one excision was 
to be performed. Usually the re-excision requires removal of a significantly greater amount of 
tissue than an initial wider excision would have, for technical reasons. Studies have shown 
patient satisfaction to be correlated with the volume of tissue removed.(166, 167)  
2.3.6 Significance of a Local Recurrence—Subsequent Treatment 
Osteen, Chen and Alpert all conclude that a simple mastectomy is the treatment option of 
choice in the face of local recurrence following BCT. Selected patients can be eligible for re-
excision plus or minus further radiation.(168-170)  
2.3.7 Significance of a Local Recurrence—Reduced Survival 
As mentioned earlier there is a significant body of literature that supports the safety in terms 
of survival for BCT. Despite that body of literature studies began to emerge that showed poorer 
survival outcomes with recurrent tumors. The papers exploring true recurrences versus new 
primaries make note that true recurrences seem to have a poorer prognosis than the new 
primaries. How to reconcile these various observations—no difference in survival in patients 
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treated with BCS and a poorer prognosis in those who do have a local recurrence continues to be 
debated. Stotter et al. conducted a power analysis and concluded that more than 10,000 patients 
would need to be randomized to a study comparing modified radical mastectomy with BCT for a 
minimum of 10 years.(171) A meta-analysis of 78 randomized treatment comparisons of 42,000 
women with a 15 year follow up was conducted by Early Breast Cancer Trialists’ Collaborative 
Group (EBCTCG) in 2005.(70) They concluded that “differences in local treatment that 
substantially affect local recurrence rates would, in the hypothetical absence of any other causes 
of death, avoid about one breast cancer death over the next 15 years for every four local 
recurrences avoided, and should reduce 15-year overall mortality”. A close examination of this 
review shows quite a range of studies that make it difficult to draw definitive conclusions. The 
conclusion the authors make regarding the benefits of improving survival are based on a 
mathematical model in which it is unclear what they mean by “local treatment that substantially 
affect local recurrence rates.” Moreover they choose to ignore the potential negative effects of 
radiation on survival. In an editorial arguing for a modification of Fisher’s alternative hypothesis 
theoretical framework Rabinovitch and Kavanagh assert that an earlier meta-analysis by the 
same EBCTCG shows “there was a highly significant reduction in the annual breast cancer 
mortality rate for patients treated with radiotherapy after lumpectomy versus lumpectomy 
alone.”(172) In a rebuttal Fisher and Anderson in turn point out that the EBCTCG meta-analysis 
in fact showed both beneficial and negative effects of radiation with no statistically significant 
overall effect (table 2.11).(17) 
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Table 2.11 EBCTCG absolute effect of radiation therapy on survival at 20 years 
Deaths  No radiation Radiation Difference 
Breast cancer related 48.6% 53.4% 4.8 X increase 
Non breast cancer related 73.8% 69.5% 4.3X decrease 
Overall  35.9% 37.1% 1.2 X increase 
  
While both sides of this discussion clearly feel that they are correct in their understanding of 
the literature the reality is that the debate is not over. In the absence of conclusive evidence the 
potential that those women who sustain a local recurrence following BCT for early stage breast 
cancer having a poorer survival compared to the group who do not, needs to be considered.  
2.3.8 Issues Around Accuracy of Surgical Margins 
There are a number of problems inherent with determining a surgical margin.(124-126) Balch 
et al. reported on their institution’s experience with using gross margin assessment at the time of 
the initial surgery by the surgeon and pathologist. They concluded that “gross examination of the 
resection specimen does not reflect margin status in at least 25 per cent of women undergoing 
partial mastectomy for breast malignancy.”(173) The common manner in which a pathologist 
determines whether a margin is positive or not is to ink the fresh breast specimen prior to fixing 
the tissue in formalin. At the time when the data for this study was collected however the most 
common practice was to fix the specimen in formalin first and then to ink the fixed specimen 
later. In an editorial addressing this issue Fisher concludes, “it is self-evident that assessment of 
margins of resection by extant methods is a limited procedure.”(174) Given the nature of breast 
tissue (primarily fat), the ink tends to seep into the cracks and crevices of the fat and can give the 
impression of a margin that is closer than is real. While this has been addressed as a concern 
there was no study found that directly looked at this question.  Many of the breast specimens 
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obtained today are harvested using a wire-guided technique because they are not palpable. In 
those specimens the sample is checked in the radiology department to be certain that the area of 
concern has in fact been removed prior to sending the specimen to the pathologist. During the 
time period when the retrospective review was conducted for this thesis the specimens were 
routinely compressed in a device especially created for this purpose (in order to get an optimal 
radiographic image). The process of compressing the fresh resected specimen risks fracturing the 
fat allowing for ink to creep closer to the tumor.(175) Current practice no longer requires 
specimen compression and the fresh tissue is inked and cut prior to fixation. Finally, the process 
of fixing tissue in formalin results in shrinkage, with the end result that the measured margin 
does not reflect the margin achieved at the time of surgery. There have been several studies 
demonstrating the importance of this issue in tissue with high elasticity but no study was found 
that examined this issue in breast specimens.  
In an attempt to minimize these concerns a variety of techniques have been advocated to try 
and optimize the accuracy of assessing surgical resection margins. Some authors have advocated 
the examination of “shaved” margins.(176-178) This has had variable results and has not evolved 
to become a standard of care partly because of concerns regarding accuracy and partly due to the 
inherent additional cost. Some authors have advocated frozen section assessment but others feel 
that this technique compromises definitive assessment and should be avoided.(179-181) 
Likewise cytological examination of surgical margins has been tried and found wanting as has 
the use of monoclonal antibodies.(182, 183) Radiographic assessments of surgical margins as 
well as gross surgical evaluation have been shown not to be reliable.(184) 
To complicate matters more not all margins carry the same significance. A narrow surgical 
resection margin for a tumor that is close to the skin, especially if an ellipse of skin is resected 
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along with the tumor, has little significance as there is no further margin to be had other than air. 
Likewise a close margin posteriorly has questionable importance as the pectoralis major fascia 
acts to some extent as a barrier and standard surgical practice would not include resecting the 
underlying pectoralis major muscle in the absence of clinical invasion.(185-187) Tumors that are 
close to these margins do not have the same implication for residual disease as tumors 
approaching a margin where residual breast parenchyma remains.   
Finally the issue of specimen orientation is one that continues to vex the pathologist today. 
Even with current methods aimed to orient the pathologist it can be a difficult task to fully 
translate exactly where the specimen came from in the three dimensional breast making 
identification of the exact location of a positive or close surgical resection margin challenging at 
best.  
2.4  Review of the Methods Used for Prognostication and Prediction in Breast Cancer 
2.4.1 Clinical Grading System 
Early on in the history of breast cancer treatment there was an awareness that breast cancer is 
not one disease but in some way a heterogeneous collection of diseases with differing clinical 
courses. It is possible to see one person with widespread metastatic disease and a primary in the 
breast that is barely detectable (or not at all) and the same day see another person with a large 
advanced tumor and no discernable metastasis.  
In our collective efforts to attempt to understand and treat this mix of disease called breast 
cancer a number of classification tools have been developed to aid in the process of 
prognostication and prediction of treatment response. The beginning of these efforts was the 
histologic grading system that continues to be the backbone of our current clinico-pathologic 
system. Most recently genetic profiling has offered new opportunities and has generated a 
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significant amount of excitement and enthusiasm, rekindling the hope of one day being able to 
find a way to truly “personalize” the delivery of care to each individual patient.  
The clinical grading system that is widely in use today, and which is the standard in 
Saskatoon, is the Nottingham combined histologic grading system (or the Elston-Ellis 
modification of Scarff-Bloom-Richardson grading system).(188) This grading system takes into 
account three different histologic characteristics and scores each one from 1-3 to give a final 
score out of 9. The grading system examines the following three areas: 
1. Tubule formation: 
If > 75% of cells arranged in tubules, then score 1. 
If 10-75% of cells arranged in tubules, then score 2. 
If < 10% then score 3.  
 2. Number of mitoses: 
The mitotic score is determined by the number of mitotic figure found in 10 consecutive 
high-power fields in the most mitotically active part of the tumor and using a table that 
takes into account the field diameter and area as these vary from one microscope to 
another. The score ranges from 1-3. 
3. Nuclear pleomorphism: 
If cell nuclei are uniform in size and shape, relatively small, have dispersed chromatin 
patterns, and are without nucleoli, then score 1. 
If cell nuclei are somewhat pleomorphic, have nucleoli, and are of intermediate size, then 
score 2.  
If cell nuclei are relatively large, have prominent nucleoli or multiple nucleoli, coarse 
chromatin patterns, and vary in size and shape, then score 3.  
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A final combined Bloom-Richardson (B-R) grade is determined by adding the scores of the 
three areas being examined giving a possible range of 3-9. A modified Bloom Richardson score 
of 3,4,5 is considered to be a low grade tumor, a score of 6 or 7 results in an intermediate grade 
designation and a score of 8 or 9 results in a tumor being called high grade.  
While there has been concern in the literature about the reproducibility of this grading system 
two well done studies show there to be quite good reproducibility between pathologists 
examining the same malignancy.( 189, 190, 191) Various studies have demonstrated that 
histologic grade is a powerful prognostic parameter despite some variation in reproducibility 
mentioned above.(192, 193) 
2.4.2 Immunohistochemical Markers 
Immunohistochemistry (IHC) is now an accepted component of modern pathology. It refers to 
the process of detecting antigens in cells of a tissue section by using tagged antibodies that bind 
specifically to antigens in biological tissues and allow the pathologist to visualize or see the areas 
that are bound. IHC is most frequently used in anatomic pathology to help determine an 
undifferentiated cell’s tissue of origin or distinguish between tumor types (the use of  
e-cadherin to distinguish duct carcinoma in situ where it stains positively from lobular carcinoma 
in situ where is stains negatively for example).  
The discovery of hormone receptors in breast carcinoma resulted in a significant improvement 
in our ability to classify breast cancer from both prognostic and treatment perspectives. Both 
estrogen (ER) and progesterone (PR) receptor levels have been found to be useful and it is 
currently the standard of care that the estrogen receptor status be measured in all invasive 
primary breast cancers.(133) ER and, to a lesser extent, PR levels are associated with a good 
prognosis. They are also predictive of response to endocrine treatment with agents such as 
tamoxifen, aromatase inhibitors, irreversible ER inhibitors and ovarian ablation.(133) 
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Despite the longstanding use of ER and PR assays in the care of breast cancer patients there 
has been a lack of standardization for these assays until recently. While these assays were 
initially biochemical assays when they were developed in the 1980’s, the current gold standard is 
IHC, performed on formalin-fixed, paraffin-embedded cancer tissue.(194) Unfortunately there is 
substantial intra, and interlaboratory variation in ER and PR results because of fixation, antigen 
retrieval, and staining methods that differ among laboratories.(135, 136) In one study comparing 
200 laboratories receiving sections from the same three reference tumors the false negative rates 
were as high as 30-60%.(195) It has been demonstrated that the duration of formalin fixation 
affects ER staining, with longer fixation times resulting in higher ER levels. Despite this there 
has been no standardized of fixation in most, if not all, laboratories until recently with the 
introduction of the College of American Pathologists guidelines in 2009.(196, 264) The method 
and duration of antigen retrieval also affect IHC results. These various concerns combine to give 
one pause especially considering that there is some data to suggest that the higher the level of 
expression of ER, the higher the probability of benefit from endocrine therapy. (197) 
There are now several methods that can reliably measure ER and PR miRNA expression. 
Most notable amongst these is quantitative reverse transcription polymerase chain reaction (RT-
PCR) and more recently DNA microarrays.(194) These are thought to be more useful not only 
because they are more reproducible but also because they also measure the expression of several 
downstream ER-regulated genes (PR, Bcl-2, SCUBE-2) that may contain information on ER 
functionality.(198) Current IHC assays give us information on the presence of ER but do not 
guarantee functional activity of those receptors. 
A number of serum tumor markers have been examined to assess their potential in aiding with 
the diagnosis and/or management of breast carcinoma. To date none of these have been found to 
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be of enough use to incorporate into current clinical practice.(133)  CA15-3, CA27 CA29, and 
CEA are the ones that have been studied the most. 
A number of IHC based markers of proliferation in breast cancer have also been studied and 
not found useful in clinical practice at this time.  The most commonly studied in this group have 
been Ki 67, TK, cyclin E, cyclin D, cyclin inhibitors p27, p21 and topoisomerase Iia.(133) 
Cathespsin D and cyclin E are two other newer assays that have been examined and found to 
be associated with a poorer prognosis but for whom enough evidence has not been accrued to 
justify them being used clinically in any way.(133)  
p53 as a marker for breast cancer deserves special attention given that it is one of the markers 
that was tested for in Saskatoon during the time period that was used in this study and given the 
importance that this gene mutation has. It is known to be the most mutated gene in cancer.(199) 
A number of studies suggest that high tissue p53 protein levels measured by IHC or PCR 
(polymerase chain reaction) are a predictor of poor outcomes.(139-142) A meta-analysis done in 
1999 suggests that p53 mutations confer an independent relative risk of 1.7 for both disease-free 
survival and overall survival.(200) IHC for p53 detects both mutated p53 and stabilized wild-
type p53 and therefore misses p53 deletions. Consequently, it seems unlikely that IHC for p53 
will provide accurate enough results to be clinically useful. This is likely a marker that will be 
useful in the future as methodologies improve and as further research more clearly defines its 
role.(133) 
Her2 is a member of the epidermal growth factor receptor family (EGFR). It is amplified and 
over expressed in 15-30% of newly diagnosed breast cancers and is associated with a more 
aggressive behavior.  Its measurement is currently considered to be standard of care for all newly 
diagnosed breast cancers.(133) Her2 is measured either by IHC or by a gene amplification 
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process (most commonly by fluorescent in situ hybridization or FISH). While Her2 over 
expression is generally associated with a poorer prognosis currently the use of Her2for 
determining prognosis is not recommended. It is however recommended to select patients for 
anti- Her2 based therapy. (133) 
Trastuzumab is a humanized monoclonal antibody that binds to the extracellular domain of 
Her2. Studies demonstrate that for Her2 positive patients, both metastatic and other wise, 
trastuzumab in addition to conventional chemotherapy has been beneficial.(133) 
Moreover evidence exists which suggests that over expression of Her2 identifies patients who 
have a greater benefit from anthracycline-based adjuvant therapy compared with CMF.(133) 
Having said that it is not clear whether Her2 itself is the target of anthracyclines or if Her2 status 
serves as a surrogate for a different gene product that may be the target of the anthracycline.  
2.4.3. Nodal Status 
It is well accepted that axillary nodal status is the most significant single factor in patient 
prognosis with node positive patients fairing significantly worse than node negative 
patients.(144, 145)  Moreover prognosis is inversely proportional to the number of positive 
nodes. 
2.4.4 Scoring Systems 
There are several scoring systems currently available that make use of clinical and pathologic 
indicators to predict prognosis and response to treatment. Adjuvant online makes use of the 
SEER database in the development of its system which relies on histologic grade, tumor size, the 
number of lymph nodes involved and the estrogen receptor status.(201) The Nottingham 
prognostic index is derived from a multivariate analysis of operable breast cancer patients in 
Nottingham.(202) While these two systems are largely equivalent there are some significant 
differences with the Adjuvant online system being somewhat more optimistic in general.  
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While these various systems are helpful in predicting prognosis and response to therapy for 
the individual patient it is not ideal.(148-150) For example approximately one-third of lymph 
node-negative patients who are currently classified as within a “good prognostic group” develop 
recurrence while a similar proportion of node-positive women remain disease free. Likewise a 
significant proportion of patients deemed to be in a “poor prognostic group” will never develop 
distant recurrence.(203) This reality has been the impetus behind research looking into 
alternative ways to achieve this goal.(135, 150) 
2.4.5 Gene Profiling 
2.4.5.1  Overview 
With the mapping of the human genome it became evident that genetic changes were at the 
heart of cancer development.(134, 135, 150-152)  In 1986 the NIH officially launched the pilot 
stage of an effort to create a comprehensive catalogue of genetic changes involved in cancer 
(The Cancer Genome Atlas or TCGA). By 2007 350 cancer-related genes were mapped in this 
ongoing work. 
One of the key technical advances that the human genome project created was the 
development of microarray analysis. A microarray is an orderly arrangement of known or 
unknown DNA samples attached to a solid support. Each DNA spot on the microarray (called the 
probe) is usually less than 200PM in diameter and an entire array typically contains thousands of 
spots.(204) There are many ways this could be done but in practice only a small number of 
formats are in common use. Of these the most common are filter arrays, glass DNA microarrays 
and high-density oligonucleotide arrays.(203) Cooper in his review of the subject goes into these 
in some detail. (204) 
Microarray technology provides a method for monitoring the RNA expression levels of many 
thousands of genes simultaneously in primary tumors and cell lines.(204) This technology has 
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enabled “discovery-based research” to be conducted, in which large volumes of data are 
generated from clinical specimens and analyzed without a specific hypothesis, in contrast to the 
traditional scientific paradigm of “hypothesis-based research” in which a limited number of 
genes/proteins are investigated based upon a specific hypothesis and rationale.(135, 154) The 
major challenge has been, and continues to be, distinguishing meaningless mutations in tumor 
samples from cancer related ones.   
Gene expression profiling has been introduced in the last decade as means by which multiple 
genes in a tumor sample may provide useful information about a given tumor’s behavior.(204) 
Breast cancer research has been at the forefront of this gene expression profiling research.(155) 
Gene expression is the term used to describe how active a particular gene is.(205) This is a 
function of how frequently it is expressed or transcribed to produce the protein it encodes. The 
first step in the process is the transcription of the gene’s DNA into messenger RNA (miRNA).  
Modern molecular biological tools measure this activity by counting the number of miRNA 
molecules in a given cell type or tissue. Counting miRNA transcripts provides an estimate of the 
number of corresponding proteins because the miRNA molecule is translated within the 
ribosome to produce a complete protein. DNA microarray and real-time reverse transcriptase 
polymerase chain reaction technologies allow simultaneous counting of many gene 
transcriptions. Gene expression profiles or signatures are lists of genes that are differentially 
expressed between normal and diseased patients. 
There are two main types of expression microarrays, cDNA microarrays and oligonucleotide 
microarrays. Both types are hybridized with cDNA or RNA samples obtained from tissue.  Real 
time PCR or qRT is an important method in the armamentarium of micro array analysis.(206) 
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This technique is particularly attractive because it can be applied to both fresh tissue and paraffin 
embedded tissue allowing for review of archival specimens.(156-158) 
In principle there are two ways that gene expression microarrays can be performed: 
unsupervised and supervised. Unsupervised analysis refers to an extensive set of methods of 
which hierarchical clustering analysis has become the most popular. The main purpose of this 
method is to identify new groupings of genes that may have clinical significance. The strength of 
these groupings is that they are not based on single genes or a specific pathway.  This 
constellation of several groups of genes then make up a  fingerprint or ‘portrait’.(203) 
Supervised analysis on the other hand requires tumor cases to be allocated to specific groups 
based on clinical or pathological features such as survival or basal cell morphology. There are in 
turn two main subtypes of supervised analysis, class comparison and class prediction.  
Hierarchical clustering algorithms group samples together based on similarity in their patterns 
of gene expression. This was the method utilized by the Stanford group in their ground-breaking 
study examining gene-expression patterns of breast cancer in which at least four major molecular 
classes of breast cancer were suggested.(155, 159) These investigators applied this class 
discovery method to data from three normal breast samples and 40 different breast tumors 
(including 20 repeated measurements from the same tumor). They selected the genes that showed 
the greatest between-sample variability. Using these 1753 genes in hierarchical clustering they 
observed two main clusters and additional smaller secondary clusters. This data led to a schema 
of four different molecular classes of breast cancer that they called luminal-like, basal-like, 
normal-like and Her2positive. They compared the four molecular classes with the tumors ER 
status. They found that the ER+ group is characterized by a higher expression of breast luminal 
epithelial cells (“luminal “ cancer). This first group has been subsequently divided into at least 
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two subgroups—luminal-A and luminal-B.  Within the ER- group three of the molecular 
subgroups dominated—one over expressing Her2, one expressing genes characteristic of breast 
basal/myoepithelial cells (basal-like cancer) and another with a gene expression profile similar to 
normal breast tissue.(198)  
Since then a number of studies have suggested further sub classification schemes.(160) Rakha 
et al summarize the currently accepted molecular classes in their review. (203)  Luminal tumors 
(ER-positive tumors) are generally subdivided into Luminal-A and Luminal-B. Luminal-A 
tumors are ER positive, make up 19-39% of tumors, have the highest expression of the ER and 
ER-related genes and show the best prognosis. Luminal-B tumors have profiles enriched for 
‘luminal genes’ but show low to moderate expression of genes pertaining to the ER cluster. They 
represent 10-23% of tumors and are associated with a less favorable outcome. ER negative 
tumors are further subdivided into three molecular and biologically distinct groups. The first of 
these, called basal-like, makes up 16-37% of tumors. Tumors from patients carrying BRCA1 
mutations fall within the basal-like subgroup. Her2 positive tumors represent 4-10% of tumors. 
These tumors express high levels of genes located in the Her2 amplican (17q11). Both the basal-
like group and the Her2 group exhibit aggressive clinical behavior and poor prognosis. Both tend 
to have high levels of p53 mutation. Finally the normal breast-like group is found in up to 10% 
of all breast cancers. These tumors have a prognosis that seems to be better than the basal-like 
cancers and do not appear to respond to neoadjuvant chemotherapy as well as other ER negative 
tumors. It is likely that further clinical sub stratification will occur.(134, 145, 160, 161) 
At the same time as this work has generated significant enthusiasm there has been a number 
of voices expressing concern. Hierarchical clustering by its very nature is rather subjective. 
Clustering algorithms always detect clusters, even in random data. As a consequence it is easy to 
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misinterpret dendritogram results.(198) McShane et al proposed a two-step approach in which a 
global test for clustering is performed and when a pattern emerges the strength of cluster-specific 
reproducibility be assessed. (207)   Applying this to the initial Stanford data demonstrated 
robustness and reproducibility only for the original four classifications. Clustering results also 
depend on the gene set that is used. It is important to use a standard gene set, otherwise 
clustering yields different results even for the same data. In addition sample size can 
significantly alter the results even when the same gene set is used for clustering. Other variables 
such as data input, choice of distance metric, and linkage can also have profound effects on the 
shape of the dendritogram generated by hierarchical clustering. 
Quite apart from the technical concerns regarding unsupervised gene expression analysis 
several significant and important questions remain unanswered. Whether or not these molecular 
subgroups really do represent a new and novel approach and how much if any additional 
information this classification system offers over traditional methods in terms of patient 
management is still unclear.(203) One could argue that what we are seeing with hierarchical 
clustering expression data is merely a reflection of the ER status, the Her2 status and the 
proliferation status that can be determined using other routinely available techniques.  At the end 
of the day we do not know yet whether or not molecular taxonomy will outperform current 
classification systems. Moreover molecular classification based on hierarchical clustering 
analysis cannot be applied prospectively. And finally we need to acknowledge that currently 6-
36% of breast cancers cannot be classified into any of the identified categories.  
In class comparison studies one compares groups of interest that are not defined by expression 
profiles. For example invasive versus in-situ cancers might be examined via a given gene 
expression profile.  Rahka et al note that class comparison studies have for the most part 
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corroborated concepts obtained by means of traditional pathology and molecular genetic 
studies.(203) 
The major aim of class prediction studies is to identify a set of key genes that can accurately 
predict the class membership of new samples based solely on that predefined predictor set. 
Within this group of studies there are again two types of studies with different goals. First we can 
identify a group of studies that use gene signatures to prognosticate and second we can identify a 
group of studies that use gene signatures to predict response to therapy. This paper will examine 
in some detail the various significant profiles in some detail.  
2.4.5.2 Clinical use 
Van’t Veer et al pioneered the concept of prognostic class prediction in their study that 
identified a list of 70 discriminatory genes.(155, 163) The “Amsterdam 70-gene prognostic 
signature” was found to be strongly predictive of a short interval to distant metastasis in lymph 
node-negative patients.(164) This 70-gene predictor is commercially available as the 
“Mammaprint” assay and is being used a clinical trial called MINDACT (Microarray in Node 
negative Disease my Avoid ChemoTherapy).  
In the development of this signature approximately 25000 genes were studied in 97 node-
negative breast cancers. A training set of 78 of these 97 tumors (34 from breast cancer patients 
who developed distant metastases during the 5 years after surgery and 44 from patients who did 
not) was used to develop the classification rule. A statistic measuring the difference in gene 
expression between the two types of tumors, with and without metastasis at 5 years, was 
calculated for each gene. The 70 top-listed genes were selected and their average expression in 
good prognosis tumors was defined as the good prognosis profile. Each of the remaining 19 
tumors from the validation set was classified according to the correlation between its 70 gene 
expressions and the good prognosis profile.  
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The Oncotype Dx assay developed and commercialized by Genomic Health was developed to 
determine the risk of recurrence in women with node-negative, ER+ breast cancer who had 
received treatment with tamoxifen and may not benefit from adjuvant chemotherapy vs. those for 
whom CMF adjuvant chemotherapy might be more advantageous than tamoxifen.(134, 151, 165, 
166)  This assay is done on formalin-fixed paraffin-embedded tissue samples and is based on the 
expression of 21 genes (16 cancer-related genes and 5 control genes). (208)   The 21 genes in 
Oncotype DX were selected from a much larger set of genes following the analysis of patients 
enrolled in the NSABP B-20 trial.(209) The levels of expression of the 21 genes are manipulated 
by an empirically derived prospectively defined mathematical algorithm to calculate a RS 
(recurrence score). This RS score is then used to assign a patient to one of three groups by 
estimated risk of distant recurrence: low, intermediate, and high. Once the algorithm was derived 
it was validated on another group of patients who were enrolled in the NSABP B-14 trial. By 
multivariate Cox-model analysis the test was a significant predictor of recurrence independent of 
age and tumor size and a significant predictor of overall survival. A large retrospective set of 
specimens from Kaiser Permanente with long follow-up was also used in the validation process.  
It is an RT-PCR assay. A trial assigning individualized options for treatment (TAILORx) is 
currently undergoing accrual with a view to validate its usefulness as a predictor of 
chemotherapeutic response in patients with ER+ node-negative tumors.(194, 210)  
Of the multiple pathways assessed by the assay, the proliferation and ER pathways are the 
most influential on the RS calculation followed by the  Her2 pathway. It should be noted that this 
assay is best suited for detecting breast cancers with a low potential for recurrence.  
The oncotype DX discovery cohort consisted of 447 stored samples from three sources. The 
test was then validated on 668 ER-positive, lymph node-negative cases of tamoxifen-only treated 
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breast cancer patients of various ages who were enrolled in NSABP B-14 trial. In this validation 
cohort 50% had tumors with a low RS, and 6.8% of these recurred at 10 years. In the high RS 
group (27% of the cases) 30.5 % recurred at 10 years. A subsequent validation study using the 
NSABP B-20 patients demonstrated that the assay predicted benefit from tamoxifen in those 
with a low or intermediate RS and benefit from chemotherapy in those with a high RS.(209)  It 
must be noted that the patients in the tamoxifen treatment arm from that analysis were the same 
patients from whom the RS was developed. 
Oncotype DX, which is approved by the California State Licensing Agency for Laboratories, 
has not been submitted to the FDA for formal approval. It is currently exempt from the standard 
review FDA requires for diagnostic kits. The test has therefore been successfully marketed 
without classic prospective validation.(165) 
The “Rotterdam” gene expression test consists of a 76-gene microarray assay that does not 
overlap with either the Oncotype DX or MammaPrint assay.(194) This assay was the result of 
studying 286 node negative patients who had not received adjuvant systemic therapy. Validation 
was performed on 171 different node negative cases. The hazard ratios for distant metastasis-free 
survival in premenopausal, postmenopausal and subsets of lesions between 1.0 and 2.0 cm were 
all statistically significant. 
The Mammaprint is a commercially available gene expression-profiling platform marketed by 
Agendia and is often referred to as the “Amsterdam” profile as it was developed there.(134, 151, 
165)  It requires fresh tissue for analysis. Analyzing primary tumors from 117 node negative 
breast cancer patients with oligonucleotide microarrays developed this assay. The data were 
subjected to supervised classification to establish a 70-gene RNA expression profile that 
correlated with a relatively short interval to distant metastases. The signature was then tested in 
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295 consecutive stage I or II primary breast cancer patients younger than 53 years of age. (Of 
note this second group included 61 patients with node negative disease used in the prior study 
that established the test). The estimated hazard ratio for distant metastases by signature was 5.1 
(p=<. 001).  
Ma and colleagues developed a “2-gene signature.”(134, 151)  It is a 6-gene multiplex 
prognostic RT-PCR assay that uses FFPE tissues. It is based on the original report of the impact 
of the ratio of the relative miRNA expression of two genes—the homeobox gene-B13 and the 
interleukin-17B receptor gene—to predict recurrence in patients with ER-positive, node-negative 
primary breast cancer. 
2.4.5.3  Concerns 
Koscielny in his critical review of microarray-based prognostic tests provides an excellent 
review of the criticism of the current micro-array research. (211)   His concerns are as follows: 
Gene lists are unstable. Taking the Amsterdam signature as an example he aptly points out 
that there is no justification for choosing particular tumors for the training and validation sets. 
They reanalyzed the original Amsterdam data at random such that different tumors were 
represented in the training and validation sets. They discovered that every set of patients led to a 
different list of genes in the signature. Ein-Dor estimated that several thousand biological 
samples would be needed to obtain a stable list of genes.(212) 
Validation of the prediction rule. Again using the Amsterdam signature as an example he 
points out that the validation population included 61 patients who were already in the first study, 
essentially invalidating the conclusions. 
The superiority of signatures over clinico-pathological parameters is not established. Using 
multivariate regression analysis as is frequently done is poor model building. He argues that the 
common practice of starting with a signature that is a significant predictor of outcome and then 
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testing to see if the addition of clinico-pathologic factors improves the model is incorrect. The 
correct model building strategy would be to comparing two models with and without the 
signature. When the later was done it was shown that the gene signature did not significantly 
improve the predictive accuracy of age, nodal involvement, ER status and tumor grade. 
In breast cancer, the available signatures lead to discordant predictions. Fan et al applied five 
gene-expression-based models to a single data set of 295 samples. (213)  The five models used 
were intrinsic subtypes (Stanford group molecular classification system), 70-gene profile 
(Amsterdam model), wound response, recurrence score (oncotype dx) and the two-gene ratio 
system. Despite the fact that these various models used very distinct gene sets with little overlap 
in terms of gene identity, there was a high rate of concordance in their outcome predictions for 
the individual samples (with the one exception of the two-gene model). This would suggest that 
these various models are probably tracking a common set of biological phenotypes. Koscielny 
however points out that among the patients with an intermediate risk according to the recurrence 
score about half of them are classified as poor-prognosis patients according to the 70-gene 
signature. He goes on to state that this 50% discordance is clearly not clinically helpful.(211) 
Most of the existing studies are significantly underpowered and the conclusions are not 
supported by the data. The fact that a gene belongs to a given signature does not make it, per se, 
a functionally and biologically relevant gene for breast cancer. Studies have suffered from bias in 
sample selection, in statistical analysis and in the analysis of data based on preconceptions of 
outcome. Some signatures have been found not to be reproducible in independent studies.(194)  
Multiple signatures have been shown to have prognostic significance in the same cohort of 
patients. Intra- and interlaboratory reproducibility of results must be determined, and the 
standardization of methodology has to be established.(134, 135, 151)  As a result of these 
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concerns the US Food and drug Administration has launched the Microarray Quality Control 
project but the result of this inquiry is still pending.(214)  
2.4.5.4 Evidence to suggest use of gene signatures in predicting local recurrence. 
There is little evidence in the literature examining the utility of gene signatures in predicting 
local recurrence following breast conserving surgery.(166, 170) Oncotype DX has been 
demonstrated in one unpublished report to predict the risk of loco-regional recurrence in node-
negative, hormone-positive women with breast cancer. The study presented at the 28th Annual 
San Antonio Breast Cancer Symposium was an evaluation of the results from the previous 
NSABP B-14 and B-20 trials in an attempt to determine whether the recurrence score from 
Oncotype DX could establish an association between loco-regional recurrence in women. They 
found that the recurrence score was a significant predictor of loco-regional relapse among the 
895 tamoxifen-treated patients who were lymph node-negative, estrogen receptor-positive (8 at 
10 years the local recurrence rates were 4.3%, 7.2% and 15% respectively for those with low, 
intermediate and high recurrence scores). The recurrence score also significantly predicted risk 
of local-regional relapse in placebo-treated patients (20% for intermediate and high recurrence 
score patients and 11% for those with a low recurrence score. 
Kreike et al looked at gene expression profiles in patients under 51 who had undergone breast 
conserving surgery.(171) They applied various methods of supervised and unsupervised analysis 
and found no signature that was predictive if ER-driven genes were taken out.  
Nuyten et al found that a supervised/optimized wound signature was found to be a robust 
predictor of local recurrence after breast conserving surgery.(172) In a multivariate model, 
including clinical and pathological variables, the wound signature was not only independent in 
predicting local recurrence, but it was also the strongest predictor overall. This observation needs 
to be verified. 
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2.4.6 MicroRNA 
MicroRNA (miRNA) are a relatively newly discovered class of single stranded non-coding 
RNA molecules that are 17-27 nucleotides in length.(173, 174)  First identified in 1993 these 
small molecules have been identified in many organisms including yeast, fruitflies, plants and of 
course humans.( 215, 216)  Bartel identified that these small miRNA play key roles in regulating 
gene expression by inhibiting translation and/or triggering degradation of their target 
miRNA.(216)  He demonstrated that RNA Pol II generally transcribes miRNA genes in the 
nucleus and gives rise to a larger primary miRNA transcript that are processed by RNase III 
Drosha to form a somewhat smaller pri-miRNA which in turn is transported into the cytoplasm 
of the cell. Once in the cytoplasm it is cleaved into an imperfect double stranded RNA termed 
miRNA/miRNA. This miRNA duplex is subsequently unwound and a mature miRNA ultimately 
binds to miRNA 3' untranslated regions. The two proposed mechanisms of expression from this 
point related to the degree of complementarities between the miRNA and its target miRNA. By 
binding to imperfect complementary sites of the target miRNA the miRNA interferes with 
protein synthesis. The second mechanism is thought to be due to endonucleolytic cleavage of the 
target miRNA by perfect base pairing, a process thought to function only in flowering plants 
until recently.  
It is estimated that the human genome contains about 1000 miRNA.(217) These miRNA in 
turn target thousands of miRNA affecting all cellular processes. They are often organized in 
tandem and found clustered on the chromosome. Over half of the miRNA are located in or near 
fragile sites or cancer associated genomic regions.(177) Calin et al reported the first link between 
miRNA and cancer in 2002.(178)  Visone and Crose point out that miRNA expression can be 
altered by several mechanisms in human cancer including chromosomal abnormalities, 
epigenetic changes, mutations and polymorphisms (SNPs), and defects in the miRNA biogenesis 
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machinery.(218) All tumors investigated to date have demonstrated altered miRNA expression. 
It is thought that this may likely implicates miRNA in oncogenesis. This process is likely via the 
regulations of oncogenes and tumor suppressor genes, cell cycle regulation, regulation of cancer 
associated signaling pathways and/or the regulation of progression and metastasis.(174, 179-182) 
The potential application of miRNA research includes areas of diagnosis and prognostication 
and potentially as a therapeutic modality.(218)  MiRNA expression profiling using techniques 
similar to those described for DNA profiling above have shown that miRNA clusters samples 
around the tissue of origin making it a powerful tool in sorting out metastatic tumors of unknown 
origin. A number of studies suggest a role for specific miRNAs in identifying disease 
progression and identifying poor prognosis tumors.  
Recent studies have shown that miRNA expression profiling may be more accurate for 
distinguishing disease states than miRNA expression analysis. (183-185) This is because 
miRNAs are better preserved, and can be obtained from formalin fixed paraffin embedded 
(FFPE) tissue. As a result it is thought that they may be a better choice for expression studies 
when using FFPE samples.(219) There are vast collections of FFPE samples of tumors available 
throughout the world as this was the method of choice worldwide for the preservation of tissue 
samples for decades now because this method maintains morphological features of the original 
tissue quite well. These collections of FFPE samples offer the potential for extensive 
retrospective analyses with significant periods of clinico-pathological follow-up provided the 
molecular information of interest is available. Unfortunately, the processes of fixation, 
embedding and storage have negative impacts on the quality of DNA and RNA that are isolated 
from these tissue samples.(219) Until quite recently there have been no pathology standards 
regarding length of time in fixation and other details such as the amount of fixative required and 
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the strength of the fixative.  At a molecular level the important issues are nucleic acid 
fragmentation and modification. Formaldehyde causes crosslinking with proteins and other 
proteins leading to a significant reduction in the RNA recovered.(220) Moreover, Formalin 
fixation and ethanol processing also leads to the production of mono-methylol and ethoxylated 
adducts with the bases of nucleic acids, as well as depurination fragments, reducing the 
efficiency of reverse transcription.(186-188)  RNA fragmentation occurs for several reasons. 
Delays that occur in getting a sample into formaldehyde result in tissue autolysis and degradation 
of RNA.(221) Likewise prolonged fixation (more than 24 hours), incubation at elevated 
temperatures during the embedding process and prolonged storage of the samples (greater than 
one year and especially at higher temperatures) results in RNA fragmentation.(219)  Because of 
their small size and possibly because of a protective protein coat miRNA’s are less susceptible to 
these effects and are more useful for expression profiling in FFPE samples that have been stored 
for a period of time.(174, 190)  
Aberrant expressions of miRNA were first reported in breast cancer by Iorio et al. in 
2005.(222) The identified 29 aberrantly expressed miRNA in their analysis of 79 breast cancers 
and 14 human breast cancer cell lines. Many of these aberrant miRNA were located at genomic 
fragile sites or regions associated with cancers.(223) Subsequently Zhang et al. also reported 
aberrant miRNA in human breast cancers.(224) The miRNA that are associated with breast 
cancer can be grouped into tumor suppressor miRNA and oncogenic miRNA. The tumor 
suppressor miRNA identified so far include Let-7 which targets Ras, and Hmga2, miRNA125a/b 
targeting ErBb2 and ErBb3, miRNA206 targeting ERa, miRNA17/20 targeting AlB1, Cyclin D 
and E2F, miRNA145 targeting RTNK, and miRNA205 targeting the HER3 receptor. The 
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oncogenic miRNA identified to date include miRNA21 targeting Tpm1 and PDCD4 and 
miRNA27 targeting ZBTB10 and Myt 1. 
The miRNA let-7 is associated with breast cancer stem cells. It is reduced in these stem cells 
and increased with differentiation, implying that let-7 can regulate self-renewal and 
tumorigenicity of breast cancer cells. Let-7 over expression in breast cancer stem cells inhibited 
cell proliferation and mammosphere formation in NOD/SCID mice.   
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CHAPTER 3 
METHODOLOGY 
3.1 Introduction 
This chapter will provide the reader with a detailed explanation of the methodology employed 
for the study that was performed for this thesis. This will include a rationale for the study design, 
the processes involved in data collection and the statistical methods used in data analysis.   
3.2  Local Recurrence in Patients with Narrow Surgical Margins 
3.2.1 Study Question 
The hypothesis of this study is that a narrow (less than or equal to 2mm) surgical resection 
margin in breast conserving therapy done for stage I and II breast cancer does not result in an 
increased local recurrence rate.   
3.2.2 Study Design  
A randomized controlled study to address the issue of narrow surgical resection margins in 
early stage breast cancer treated with BCT is not possible. To do so one would need to 
randomize patients to one of two arms—wide excision with a surgical resection margin of 
greater than two mm and narrow margin excision with a surgical resection margin that was 
negative but less than or equal to two mm. Even if surgeons were capable of that degree of 
precision (which they are not) such randomization would be unethical.  
It is conceivable that one could design a study where in all women who had a lumpectomy 
with a surgical resection margin less than or equal to 2 mm. were randomized to further wide 
excision or no further surgery, controlling for other variables known to be associated with 
increased local recurrence.  This study design would be the one most likely to allow for 
resolution of the question and to assign causation to the results. Moreover, being prospective, it 
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would allow for the incorporation of newer molecular methods of tumor classification to be part 
of the final analysis. While such a randomized prospective study would offer the strengths 
mentioned above, there are several challenges that would make it very unlikely to be able to 
successfully conduct such a study. The 10 years it would take to wait for results would itself be a 
serious challenge to conducting such a prospective study. Furthermore, given that the question 
being asked is about local recurrence and not survival it is unlikely that the required funding to 
perform the study could be found. Finally, it would be difficult to recruit enough people to agree 
to be randomized into the two arms of the study (re-excision versus no further surgery) in the 
absense of adequate literature on the topic to stress the need for such a randomized study. The 
perception that one should “do everything” would almost certainly hamper recruitment.  
Having accepted that a prospective randomized trial was not feasible the study design felt 
most appropriate in the hierarchy of study designs was that of a retrospective cohort design. This 
study design was deemed feasible and was therefore chosen.  
3.2.3 Inclusion and Exclusion Criteria 
In order to minimize bias in the selection of the two cohorts inclusion and exclusion criteria 
were established. The patients included in the study were patients with a diagnosis of invasive 
duct carcinoma of the breast in stage I or II as defined by the American Joint Committee on 
Cancer seventh edition (AJCC), treated with breast conserving therapy.(225) Breast conserving 
therapy was defined as surgical removal of the malignant tumor with a negative surgical 
resection margin and postoperative radiation to the whole breast using a standard radiation 
protocol. As BCT is standard treatment only in stage I and II breast cancer (early stage breast 
cancer), inclusion was limited to these patients. The AJCC define tumor stage based on the TNM 
system where T refers to tumor size, N refers to the nodal status and M stands for the metastatic 
status. Stage I breast cancers are composed of all T1N0M0 cancers, where T1 refers to tumors 2 
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cm. or less in greatest diameter, N0 indicates no regional modal metastasis, and M0 indicates no 
distant metastasis.. Stage II breast cancers are divided into two groups—IIA and IIB. Stage IIA 
cancers are those which are T0N1M0, T1N1M0, or T2N0M0 while stage IIB cancers are those 
which are T2N1M0 or T3N0M0. T0 indicates that no tumor is identified in the breast, T1 refers 
to cancers less than 2 cm in diameter, T2 refers to cancers more than 2 but less than 5 cm in 
maximum dimension, and T3 refers to cancers more than 5 cm.  N1 refers to metastasis in 1 to 3 
axillary lymph nodes.  
There are several different histological diagnosis of breast carcinoma that imply either a better 
or worse prognosis.(138) Medullary carcinoma accounts for about 4% of all breast cancers and is 
characterized histologically by a dense lymphoreticular infiltrate composed predominately of 
lymphocytes and plasma cells, large pleomorphic nuclei that are poorly differentiated and show 
active mitosis, and a sheet-like growth pattern with minimal or absent ductal or alveolar 
differentiation. This histologic type is a frequently seen in BRCA-1 hereditary breast cancer and 
has a better five year survival than invasive duct carcinoma. Mucinous or colloid carcinoma 
accounts for about 2% of all breast cancers characterized by extracellular pools of mucin 
surrounding aggregates of low-grade cancer cells. Papillary carcinoma is another good risk 
breast cancer that makes up about 2% of the overall total of invasive breast cancer. These tumors 
are characterized by papillae with fibrovascular stalks and multilayered epithelium. Tubular 
carcinoma is another special histologic group making up about 2% of the total and carrying a 
better prognosis. Micropapillary carcinoma is a more recently recognized histologic type which 
carries with it a poorer prognosis.  
Several other rare histologic types have been described.  Amongst the carcinomas acinic cell 
carcinoma, adenoid cystic carcinoma, and squamous cell carcinoma are described. In addition 
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one can occasionally find a primary lymphoma of the breast or a primary mesenchymal tumor 
(sarcoma).  In recent years the boundaries between histologic classification of tumors and the 
genetic classification has become blurred with the description of a Basal-like carcinoma. This 
entity is characterized by a strongly staining basal group of cells and by staining negatively for 
estrogen receptors, progesterone receptors and the Her2 receptor and frequently corresponds to 
basal like genetic type. It carries a worse prognosis than other breast cancers.  
Lobular carcinomas make up about 10% of all breast cancers and clinically are associated 
with multifocality, multicentricity and bilaterality. While the prognosis of lobular carcinoma is 
similar stage for stage with invasive duct carcinoma the association with multifocality and 
multicentricity would make it difficult to compare this tumor subset with invasive duct 
carcinoma in terms of local recurrence.   
In order to avoid the bias of one group having more patients with a better or worse prognosis 
tumor inclusion was restricted to the most common histological diagnosis of invasive duct 
carcinoma.  
3.2.4 Sample Size Calculation 
The World Health Organization manual entitled “Sample size determination in health studies. 
A practical manual” was used to aid in determining the sample size required.(226) The formula 
used was 
> @^ `21 1 1 2 21 2 1 2
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value of Relative Risk (RR) was considered to be 1, where Relative Risk = P1/P2. The 
anticipated probability of recurrence given a wide surgical resection margin was considered to be 
10% at 10 years based on the literature (P1=0.10). The anticipated probability of recurrence given 
a narrow surgical resection margin was considered to be 15% (P2=0.15). The anticipated relative 
 74 
risk was 0.5. The level of significance was chosen to be 5% (p=.05) and the power of the test was 
fixed at 80% (80% confidence of correctly rejecting the null hypothesis (RR=1) if it is false). For 
a two-sided test the sample size calculation determined that 200 patients would be required in 
each arm of the study (narrow margin and wide margin) to detect a 50% difference in LR 
assuming a baseline 10% incidence of LR over 10 years.  
3.2.5  Definition of Local Recurrence 
Local recurrence was defined using a modification of that offered by Abd-Alla et al. in which 
an ipsilateral breast recurrence was considered a true recurrence if it was located within 3 cm of 
the primary tumor bed and had a histological subtype consistent with the primary tumor.(47)  
Given the retrospective nature of this study it was impossible to determine if a given recurrence 
was within 3 cm of the primary tumor bed. Consequently the definition used in this study for a 
local recurrence was an ipsilateral breast recurrence that had a histological subtype consistent 
with the primary tumor. Tumor recurrence in the opposite breast, metastatic breast recurrence, 
nodal recurrence, tumors where the “recurrence” was of a different histology from the primary, 
chest wall recurrence without recurrence in the breast parenchyma and isolated skin recurrences 
were not considered to be local recurrence.  
3.2.6  Study Period 
To adequately examine the question of local recurrence it was decided that a minimum10 year 
follow up period was required. Local recurrence in early stage breast cancer is a cumulative 
event with increasing incidence over time. Most studies in the literature that examine the 
question of local recurrence in breast cancer consider 10 years to be adequate and that was 
accepted as a reasonable time frame to consider.  
All patients treated at the Saskatoon Cancer Agency during the years of 1991-2001 that fit the 
inclusion criteria were included in this study. This time frame was chosen for three reasons. First, 
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by ending the data collection in 2001, the chosen timeframe allows for a minimum 10 years of 
follow-up.  The start date established for our data collection was determined by a combination of 
the above sample size calculation described above, and an estimation of the number of patients 
that would meet the inclusion criteria that was based on an initial review of the number of cases 
being registered at our Cancer Center.  The sample size calculation combined with the initial 
review led us to predict a need for 10 years worth of patient data.  Finally, during the time period 
chosen it was not standard practice to re-excise narrow margin specimens; hence an assumption 
was made that it would be possible to accrue the required number of narrow margin cases. 
3.2.7 Radiation Dose 
The standard radiation dose given was 5,000 Gy administered to the whole breast over a 5 
week period divided into 25 daily sessions of radiotherapy Monday to Friday with a rest on the 
weekends. The standard boost of radiation was a further 1,000 Gy given over 5 days.  
3.2.8  Ethics Approval  
Ethics approval was obtained from the University of Saskatchewan Health Research Ethics 
Board  (#08-60) as well as the Saskatchewan Cancer Agency and the Saskatoon Health Region.  
3.2.9 Data Collection 
 The charts of all patients treated at the Saskatoon Cancer Agency during the years of 1991-
2001 with a diagnosis of stage I or II breast cancer and a histological diagnosis of invasive duct 
carcinoma of the breast were reviewed to determine whether the inclusion criteria were met. 
Patients who went on to have a mastectomy, who had a different diagnosis, who had a more 
advanced stage, who had a positive resection margin or who did not have radiation treatment 
were excluded from further analysis. For the remainder the last date of follow-up or local 
recurrence was recorded as the primary endpoint and was considered the dependent variable in 
the statistical analysis.  
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The margin status was determined by reviewing the pathology report. In cases where the 
pathologist had recorded the margin this was taken to be accurate and valid. This assessment was 
done on formalin fixed, paraffin embedded specimens. In cases where there was a re-excision 
and there was no residual tumor in the re-excised specimen the margin was considered to be 
greater than 2mm and was recorded as “ wide margin on the basis of re-excision”. In cases where 
the margin status could not be determined from the chart the slides were retrieved and 
independently reviewed. In those cases where the pathologic review could not be determined this 
was recorded as being unable to assess.  
Based on the literature survey other variables considered to be associated with LR included 
estrogen receptor status, tumor grade, tumor size, age, the presence of extensive duct carcinoma 
in situ, radiation boost, and adjuvant chemo or hormonal therapy. Data on these variables were 
collected. Other information gathered included the date of surgery (which was used as a 
surrogate for the date of diagnosis), the name of the surgeon, the name of the pathologist, follow 
up details including the date of death or last follow-up visit, the presence or absence of 
metastatic disease (and if so when), and the management of any local recurrence (none, wide 
excision, mastectomy, further chemo/hormonal therapy), and any new or other primary cancer 
diagnosis.  
The data was collected on individual data sheets and the information transcribed into a 
database created using Microsoft access.  
3.2.10 Statistical Analysis 
3.2.10.1 Overview 
The dependent variable in this study is dichotomous (local recurrence or no local recurrence). 
In addition there are several variables that need to be considered as possible confounding or 
interacting causes of local recurrence in early stage breast cancer treated with BCT. In order to 
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address the main variable of interest and other possible variables logistic regression analysis was 
the appropriate statistical analysis to use. Given that recurrence over time was the end point 
survival analysis both with the Kaplan-Meier technique as well as the Cox Proportional Hazards 
Model were also conducted. All statistical analysis was conducted with the aid of the SPSS 18 
software package.  
3.2.10.2 Logistic Regression 
Linear regression is not an appropriate statistical methodology to test the strength of an 
association between two variables when the dependent variable is dichotomous. As in many 
health science related research this study’s variable of primary interest or dependent variable 
(local recurrence) was dichotomous. Logistic regression is a mathematical modeling approach 
that can be used to describe the relationship of several X’s to a dichotomous dependent variable. 
While other modeling approaches are possible, logistic regression is by far the most popular 
because the logistic function, on which the model is based, provides an estimate that must lie in 
the range between zero and one and it creates an appealing S-shaped description of the combined 
effect of several risk factors on the risk for a disease. In logistic regression two questions are 
addressed. The first question is whether or not an association exists between two variable of 
interest and the second is the strength of that association. Chi-square analysis is used to answer 
the first question and the odds-ratio to answer the second.(227) 
In order to create a linear transformation of the logistic model an alternative way of writing 
the model is first performed. This form of the model is called the logit form. Denoted as logit 
p(x) this form is produced by the natural log of the quantity p(x) divided by one minus p(x), 
where p(x) denotes the logistic model. The mathematical equation is log[p(x)/1-p(x)]=log(odds) 
=ȕ0+ȕ1 *x. The odds ratio is then derived from this equation wherein log[p(x)/1-p(x)]=log(odds) 
=ȕ0+ȕ1 *x.(227) 
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In logistic regression the least squares estimators for the model parameters are not used 
because variance of the dependent variable is not constant across the values of the predictor 
variable, the least squares estimates are not efficient and the standard error estimates are not 
consistent. Instead the maximum likelihood method is used to produce estimators that are 
consistent, asymptotically efficient and asymptotically normal.(227) The likelihood function that 
was thus created achieves that. 
In logistic regression the likelihood ratio test (LRT) is used to compare two models that 
contain different variables of interest fitted to the same data by the maximum likelihood method. 
The LRT is used to test the null hypothesis that the model with more parameters is not a 
significantly better model than the model with fewer parameters. By comparing different models 
one is able to find the one that best describes the relationship between the dependent variable and 
a number of independent variables of interest. (227) 
In addition a researcher needs to consider the possibility of both confounding and interaction 
of variables. Confounding exists if meaningfully different interpretations of the relationship of 
interest occurs when an extraneous variable is ignored or included in the regression mode. An 
assessment of confounding is done by comparing a crude and an adjusted estimate of association 
(the crude estimate ignores the extraneous variable of interest while the adjusted estimate 
includes it). A meaningful difference is, in the end, a clinical judgment but generally a 20% 
difference between is considered meaningful. Interaction is tested for by adding an interaction 
term to the model and comparing models using the LRT to see if the addition of the interaction 
term contributes significantly to the prediction of the outcome variable.(227). 
For this study therefore, first a univariate analysis was performed for each variable of interest. 
For each variable considered the data was analyzed at the 10 year follow-up point.  For 
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categorical variable a chi-square test was conducted whereas a t-test was used to examine 
continuous variables. Following the univariate analysis all variables that were either clinically 
important based on the literature review or those with a p  .20 were included in the 
multivariable analysis or statistical modeling. Using the Likelihood Ratio Test various models 
were compared to arrive at the best model that predicted Y (local recurrence). Having completed 
that further modeling was done to take into account the possibility of confounding and/or 
interaction effects.  
3.2.10.3 Kaplan-Meier Survival Curve 
When the outcome variable of interest is time until an event occurs the data can and should 
ideally be analyzed using a collection of statistical procedures collectively called survival 
analysis. Censoring (a key data analytical problem) occurs when we have some information 
about individual survival time but we do not know the survival time exactly. Using the intuitive 
approach of either using follow-up time regardless whether it is censored or not, or only using 
complete data results in underestimating the survival time either by reducing survival time or by 
selection bias. Survival curve estimates can either be achieved by using a life-table estimate that 
use grouped or ungrouped data and estimates survival at arbitrary intervals or by using a product-
limit estimate (the Kaplan-Meier estimate) that uses ungrouped or individual data and estimates 
survival at each time an event is observed. The Kaplan-Meier method was chosen to analyze the 
data in the study done for this thesis. While there was a minimum follow-up period of 10 years 
some patients were followed as long as 20 years. The log-rank test was performed to test for 
statistical equivalence between the curves generated. This test is a large-sample chi-square test 
comparing the curves.(228)  
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3.2.10.4 The Cox Proportional Hazards Model 
The Cox proportional hazards model is a popular mathematical model used for analyzing 
survival data that includes multiple variables. A key reason for the popularity of the Cox model 
is that, even though the baseline hazard is not specified, reasonably good estimates of regression 
coefficients, hazard ratios of interest, and adjusted survival curves can be obtained for a wide 
variety of data situations. The Cox proportional hazards model is preferred to logistic regression 
modeling when analyzing survival data because it takes into account survival times and 
censoring.(228) 
The two primary quantities desired from the Cox model are an estimate of hazard ratios and 
an estimate of survival curves. A hazard ratio (HR) is defined as the hazard for one individual 
divided by the hazard for a different individual. When a Cox model is used to fit survival data, 
survival curves can be obtained that adjust for the explanatory variables used as predictors, with 
the value chosen for the adjusted covariate typically being the mean value.  
The Cox model makes use of maximum likelihood (ML) estimates generated from a computer 
program (in this case SPSS 18). As with logistic regression the ML estimates of the Cox model 
parameters are derived by maximizing a likelihood function, which is a mathematical expression 
describing the joint probability of obtaining the data actually observed on the subjects in the 
study as a function of the unknown parameters in the model being considered. The likelihood 
ratio test can be used in the Cox model very much like the likelihood ratio test for the logistic 
regression model, where we compared the -2log likelihood values between different models. 
Variable selection for the various models is the same as is used for logistic regression.  
The underlying assumption of the Cox proportional hazards model is that the hazards are 
proportional over various time points. This implies that the cumulative survival curves and the 
hazard curves for groups do not cross. This assumption needs to be checked for validity in order 
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to use the information derived from the model. There are three general approaches that can be 
used to assess the proportional hazards assumption—graphical, goodness of fit test and using 
time-dependent covariates.  
The dependent variable in this study is dichotomous (local recurrence or no local recurrence). 
In addition there are several variables that need to be considered as possible confounding or 
interacting causes of local recurrence in early stage breast cancer treated with BCT. In order to 
address the main variable of interest and other possible variables logistic regression analysis was 
the appropriate statistical analysis to use. Given that recurrence over time was the end point 
survival analysis both with the Kaplan-Meier technique as well as the Cox Proportional Hazards 
Model were also conducted. All statistical analysis was conducted with the aid of the SPSS 18 
software package.  
3.2.10.5 Variable coding 
The coding of the variables are found in table 3.1. In some of the cases included in the study 
p53 status and Bcl-2 status was available. Given that this information was available in only a 
minority of the cases and given that the literature did not support them being significant 
independent variables they were not included in the analysis. The margin of resection was 
recorded categorically as four categories. The narrow margin group was divided into less than or 
equal to 1 mm and 1-2 mm. so that the different narrow margin widths could be interrogated 
even though it is acknowledged that the two sub-groups need to be taken together to attain 
adequate power based on the sample size analysis. The wide excision group was divided into two 
based on how the designation of wide excision was achieved (by initial resection or re-excision). 
This was done because of some literature suggesting that re-excised tumors might have an 
increased local and distant failure. While tumor size as a variable was recorded as a continuous 
variable it was decided to examine this as a dichotomous variable based on T size as has been 
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done elsewhere in the literature in order to allow for comparison. Likewise age was made into a 
dichotomous variable as is the norm in the literature. Age 40 was chosen for the cut off point for 
“young age”. All patients 40 years of age or less were considered young while those over the age 
of 40 were not. Estrogen receptor status was considered positive if 10% or more of the nucleus 
stained positive. This cut-off reflects the sensitivity of the test available at the time the data was 
collected.   
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Table 3.1 Coding of dependent and independent variables. 
Variable Coding Type of variable 
Dependent variable (Y) 
Local recurrence of breast cancer No=0 
Yes=1 
dichotomous 
Independent variables (X) 
Surgical resection margin (X1) Less than 1mm=0 
1-2 mm=1 
greater than 2 mm (measured)=2 
greater than 2 mm (re-excised)=3 
categorical 
Radiation boost (X2) No=0 
Yes=1 
dichotomous 
Tumor grade (X3) Grade 1-0 
Grade 2=1 
Grade 3=2 
categorical 
Tumor size (X4)  2 cm =0 
2.1-5 cm =1 
dichotomous 
Extensive DCIS (X5) No=0 
Yes=1 
dichotomous 
Lymphovascular invasion (X6) No=0 
Yes=1 
dichotomous 
Estrogen receptor status (X7) Negative=0 
Positive=1 
dichotomous 
Progesterone receptor status (X8) Negative=0 
Positive=1 
dichotomous 
Her2 status (X9) Negative=0 
Positive=1 
dichotomous 
Age (X10)  age 40 =0 
>age 40 = 1 
dichotomous 
Chemotherapy or hormonal therapy 
(X11) 
None =0 
Hormonal therapy = 1 
FAC =2 
Other chemo = 3 
categorical 
Lymph node status (X12) None =0 
Some =1 
dichotomous 
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CHAPTER 4 
RESULTS  
 
4.1 Introduction 
In the 10-year study period 3960 patients were registered with the Saskatoon Cancer Agency 
with a diagnosis of breast cancer. From the cancer center registry of these 3960 patients it could 
be determined that 2,872 were either stage III or IV, had a mastectomy as their initial surgical 
procedure, had a diagnosis other that invasive duct carcinoma or failed to receive adjuvant 
radiation. These 2,872 patients were excluded from further analysis. The charts were reviewed in 
all of the remaining 1088 patients. 
Of the charts reviewed a further 263 were excluded. The majority of these were excluded 
because they went on to a mastectomy after their initial segmental resection. Other reasons for 
exclusion included: misclassification (wrong diagnosis, advanced stage, incomplete or no 
adjuvant radiation) or inability to locate the chart in 25. The details of these exclusions are found 
in table 4.1.  In the remaining 825 charts there were 312 in which the surgical margin was 
measured in the original pathology report (164 greater than 2 mm and 148 less than or equal to 2 
mm), 249 in which there was a re-excision in which no residual tumor was detected, and 264 
cases in which the report was unclear and required an independent pathologic review. Amongst 
the 264 reviewed cases 134 were unable to be assessed either because the slides were lost, the 
margin was never marked, or the stain had faded to an extent that it was impossible to tell. Figure 
4.1 shows the exclusions that were made based on the registration data. Table 4.1 shows the 
further exclusions that occurred after the charts were reviewed including the reasons for the 
exclusions. Figure 4.2 takes a closer look at the 1088 patients that were included in the study and 
the disposition of those cases. 
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Figure 4.1 Chart depicting patient inclusion/exclusions based on registration data 
 
Table 4.1 Reasons for exclusions following chart review   
Indication Number 
Went on to a modified radical mastectomy 215 
Wrong diagnosis   6 
No radiation   3 
Positive margin   2 
Outside of study time frame   2 
Surgery out of country   1 
Advanced stage   8 
Unable to locate the chart  25 
Total 263 
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Figure 4.2  The disposition of the 1088 reviewed charts. 
4.2 Data Collection. 
In reviewing the charts demographic information as well as detailed information from the 
pathology report and follow up data was collected. The following was collected for each chart: 
identifying data (name, cancer center chart number, hospitalization number) 
date of birth 
date of diagnosis 
histologic diagnosis 
tumor size in cm 
ER status 
PR (progesterone receptor) status 
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tumor grade 
adjuvant radiation treatment 
adjuvant chemotherapy or hormonal therapy 
recurrence and if so the details of what kind of recurrence and when 
date of death or last follow-up 
presence or absence of extensive duct carcinoma insitu 
margin status 
name of the pathologist 
name of the surgeon 
A database was created using Microsoft access and all of the above data was entered.  
The data that was available on age was continuous. The literature generally considers age of 
40 as the discriminating point with younger age women having a higher risk of local recurrence. 
In doing our assessment age was examined both as a dichotomous variable (less than or equal to 
40 or greater than 40) as well as a continuous variable. Age was available for all cases. 
As mentioned in the literature survey grade was divided into 3 categories according to the 
modified Bloom-Richardson grading system. Higher grades are associated with increased local 
recurrence. Grade was available for all cases. 
During the study period examined a number of different chemotherapy regimes were used. 
Some women received Tamoxifen only (an anti estrogen drug), some received Taxotere based 
chemotherapy and the majority received FAC (5-flurouricil, adriamycin, and 
cyclophosphamide). The breakdown is seen in Table 4.2. Because of this variation the univariate 
analysis for adjuvant therapy was done in more than one way. The simplest examination was 
dichotomous—adjuvant therapy or not. The data was then analyzed broken down into 3 
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categories with 0=nothing 1=hormonal therapy and 2= chemotherapy. There were no cases 
missing data. The literature demonstrates that adjuvant chemotherapy and hormonal therapy is 
associated with less local recurrence. Only 24.6% of our patient population received adjuvant 
hormonal therapy and another 20.9% received adjuvant chemotherapy. Those numbers are low 
compared with what one would see in a modern oncology practice.  
Table 4.2 Descriptive analysis of adjuvant systemic therapy usage 
Type of treatment Number of patients (%) 
None  449 (54.4) 
Hormonal 203 (24.6) 
Chemotherapy--total 173 (20.9) 
Chemotherapy--FAC  44 (5.3) 
Chemotherapy--CMF  87 (10.5) 
Chemotherapy--other  42 (5.1) 
 
Both positive estrogen receptor status and progesterone receptor status have been associated 
with better prognosis and decreased local recurrence. The receptor status was available for the 
majority of cases examined and where it was missing this was recorded as missing using 99. 
Both of these were examined as dichotomous variables with 0=negative and 1=positive.   In the 
majority of cases the estrogen and progesterone status was recorded as either positive or 
negative. In a minority of cases an immunohistochemisty score of 0-4 was recorded in which 
case any score of 1-4 was  considered positive. During the time period that data was collected for 
this study a positive score equate to 10% or more of the cells being positive for the receptor. 
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Radiation boost to the tumor bed was not a common practice during the study period. It is 
now recognized that a boost of radiation to the tumor bed can decrease local recurrence from 
about 10% in 10 years to 6% in the same time period but at a cost in terms of side effects. 
Radiation boost was examined as a dichotomous variable with 0=none and 1=radiation boost.   
The presence or absence of extensive duct carcinoma in situ (DCIS) was available. An 
assumption was made that where it was not recorded as such it did not exist but this assumption 
may or may not be a valid as extensive DCIS was not routinely reported prior to 1998 in 
Saskatoon.  Extensive DCIS is associated with increased local recurrence. This was examined as 
a dichotomous variable with 0=none and 1=positive. DCIS at the margin was not routinely 
reported. 
It was a bit challenging to decide how best to measure margin status, the primary independent 
variable of interest. Ideally an independent expert breast pathologist would have reviewed all of 
the pathology by pulling the old slides and re-examining them. Unfortunately this was not 
practical with the number of cases that we had. In consultation with our breast pathology expert 
it was decided that cases where the original pathologist measured the margin or stated that the 
margin was “widely clear” we would assume that the report was an accurate reflection on reality. 
In all cases where there was a re-excision and there was no further residual tumor identified in 
the re-excised specimen it was decided that this likely represented a wide surgical resection 
margin, but to reflect the assumptions made these cases were recorded as a wide excision by 
virtue of it being re-excised. All other cases had the original sides pulled and reviewed by one of 
two pathology residents supervised by Dr. H. Reese, our local breast pathology expert. In this 
later group of patients some of the slides could not be located, in some cases the ink had faded so 
badly that the margins could not be assessed and in other cases the margin was never inked 
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making margin assessment impossible. These cases were classified as “unable to assess” and 
excluded from further analysis. The breakdown of the re-examined cases is found in Table 4.3. 
Table 4.3 Overview of the 264 pathologically reviewed slides 
Unable to assess Wide margin Narrow margin 
34 78 52 
 
While data was collected on p53 status, Bcl-2 status, and Her2 status the vast majority of 
cancers did not have these markers tested and as such it was not feasible to include them in the 
multivariable analysis. None of these were associated with increased or decreased local 
recurrence in the existing literature and therefore this was considered a reasonable decision to 
make.  
Table 4.4 lists the various margin categories broken down into local recurrence or not along 
with the percentage of local recurrence for each category.  
Table 4.4. Local recurrence rates for narrow and various wide excision groups 
 Local recurrence (%) Total % Local recurrence 
Narrow margin 19 201  9.5% 
                              < 1 mm  5  47 10.6% 
                               1-2 mm 14 154  9.1% 
Wide margin 56 500 11.2% 
                         measured 21 261  8  % 
                   by re-excision 35 239 14.6% 
Total 75 701  
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4.3 Data Analysis 
4.3.1 Overview 
Data analysis was done using logistic regression, Kaplan-Meier survival curve and the Cox 
Proportional Hazards Model.  
4.3.2 Logistic Regression 
Logistic regression was chosen because the dependent variable, local recurrence, was 
dichotomous. That is to say, either there was local recurrence or not (0=no local recurrence and 
1= local recurrence). 
 First the independent variable of primary interest (margin status) was examined in relation to 
the dependent variable (local recurrence) at 10 years.  Narrow margin status was considered as 
less than or equal to 2 mm. This groups was further divided into less than or equal to 1 mm and 
1-2 mm but given the small numbers in each of these two groups (Table 4.4) the analysis 
comparing narrow margins was done with the two groups combined in order to have adequate 
numbers to meet the sample size calculation done earlier. Because of concerns about the validity 
of assuming that a wider excision without residual cancer in the re-excised specimen could safely 
be considered a true wide excision it was decided to do this analysis in two ways. In the first 
analysis the measured and re-excised wide margins were grouped together into one group called 
wide margin. In this scenario the two dichotomous groups were 0=less than or equal to 2 mm 
resection margin and 1 = greater than two mm resection margin.  This showed that margin of 
resection did not significantly contribute to the prediction of local recurrence (p=.499). In a 
second run 3 categories of assessment for this dichotomous independent variable (0=less than or 
equal to 2 mm resection margin, 1=greater than 2 mm measured by a pathologist, 2=greater than 
2 mm by virtue of a wider excision in which there was no residual tumor). The univariate 
analysis of this independent variable of primary interest is shown in Tables 4.5, 4.6 and 4.7.  This 
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univariate analysis showed that re-excised wide margins compared with measured wide margins 
did significantly contribute to the prediction of local recurrence (p=.02) while narrow margin 
compared with either measured or re-excised wide margins did not. 
Table 4.5 Statistical analysis of local recurrence by margin status --wide excision vs. narrow 
margin 
Margin OR (CI)            p value 
Narrow margin vs wide margin measured 
and re-excised 
1.208 (.698-2.090) 0.499 
Table 4.6 Statistical analysis of local recurrence by margin status with narrow margin as the 
reference group compared with wide excision measured and re-excised wide excision 
Margin OR (CI)            p value 
Narrow margin vs measured wide 0.838 (.48-1.605) 0.594 
Narrow margin vs re-excised wide 1.643 (.908-2.974) 0.101 
Table 4.7 Statistical analysis of local recurrence by margin status with re-excised wide margin as 
the reference group compared with narrow margin and measured wide margin 
Margin OR (CI)            p value 
Re-excised wide margin vs. narrow 
margin 
0.608 (.336-1.101) 0.101 
Re-excised wide margin vs. measured 
wide margin 
0.510 (.288-.904) 0.021 
 
The second step taken was to do a univariate analysis of the various independent variables 
that had been identified in the literature as having an association with local recurrence (age < 40, 
grade, adjuvant chemo or hormonal therapy, estrogen and progesterone receptor status, radiation 
boost, tumor size, and the presence of extensive duct carcinoma in situ). This univariate analysis 
is presented in Table 4.7. Only re-excised wide margin compared to measured wide margins, 
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high grade compared with low grade and age <40 were found to be statistically significant in that 
univariate analysis. 
Table 4.8 Univariate analysis of variables  
Variable Odds ratio (CI) p value 
size (T1 vs T2) 1.401 (.844-2.325) 0.139 
Size in cm with <1 as reference 
< 1cm 1  
1-2 cm .995 (.599-1.653) 0.948 
2.001-3 cm 1.16 (.589-2.285) 0.667 
3.001-4 cm 2.011 (.811-4.988) 0.131 
4.001-5 cm 2.463 (.488-12.419) 0.275 
Size in cm with 4.001-5 cm as reference
< 1cm .406 (.081-2.047) 0.275 
1-2 cm .404 (.081-2.012) 0.268 
2.001-3 cm .471 (.089-2.497) 0.376 
3.001-4 cm .817 (.139-4.813) 0.823 
4.001-5 cm 1  
Grade with high grade (grade 3) as reference 
grade 1 .406 (.214-.770) 0.006 
grade 2 .679 (.393-1.171) 0.164 
grade 3 1  
Grade with low grade (grade 1) as reference   
grade 1 1  
grade 2 1.673 (.929-3.012) 0.086 
grade 3 2.466 (1.299-4.680) 0.006 
Margin of resection with re-excised wide margin as reference 
narrow .608 (.336-1.101) 0.101 
wide .510 (.288-.904) 0.021 
wide by re-excision 1  
Margin of resection with narrow margin as reference
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Variable Odds ratio (CI) p value 
narrow 1  
wide .838 (.438-1.605) 0.594 
wide by re-excision 1.643 (.908-2.974) 0.101 
Extensive DCIS (yes/no) .596 (.291-1.220) 0.157 
DCIS status with extensive as reference 
none .648 (.314-1.336) 0.24 
focal .393 (.157-.981) 0.045 
extensive 1  
DCIS status with none as reference
none 1  
focal .606 (.313-1.175) 0.138 
extensive 1.543 (.749-3.180) 0.24 
Nodal status (positive vs. negative 1.458 (.908-2.342) 0.119 
ER status (positive vs. negative) 1.003 (.991-1.016) 0.595 
PR status (positive vs. negative) 1.002 (.989-1.014) 0.805 
Radiation boost (yes vs. no) 1.360 (.702-2.634) 0.362 
Chemotherapy/hormonal therapy status  
(yes vs. no) 
1.087 (.701-1.686) 0.708 
Chemotherapy groups with other chemotherapy as reference 
hormonal .388 (.155-.971) 0.043 
AC .671 (.211-2.130) 0.499 
CMF .490 (.174-1.379) 0.177 
other 1  
Chemotherapy groups with hormonal as reference
hormonal 1  
AC 1.728 (.639-4.668) 0.281 
CMF 1.262 (.540-2.954) 0.59 
other 2.574 (1.030-6.437) 0.043 
Age (less than or equal to 40 vs. over 40) 2.821 (1.371-5.804) 0.005 
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Having completed the univariate analysis all variables with a p value greater than 0.2 or 
having been identified in the literature as being associated with local recurrence were included in 
the full multiple variable mode. This full model, which is presented in Table 4.9, included 
margin status (3 categories with narrow margin as reference), size status (T1 vs T2), age status 
(less than or equal to 40 vs greater than 40), grade status (3 categories with high grade as 
reference), chemotherapy/hormonal therapy status (yes vs. no), extensive DCIS status (yes vs. 
no), nodal status (positive vs. negative) and radiation boost (yes vs. no). The -2LL for the full 
model was 418.251. The -2LL with no variables was 438.049 with the difference being 19.798. 
The tabulated chi square with 10 degrees of freedom is 18.307. Given that the calculated value is 
greater than the tabulated value we can reject the null hypothesis and conclude that the overall 
model does predict local recurrence. From this point further models in which a variable was 
removed to identify which variable(s) contributed most to predicting local recurrence were 
constructed. This data is presented in Table 4.10.  
Of all the variables only high grade compared with low grade significantly contributed to the 
overall model. The remainder of the variables could be eliminated with no effect. Therefore the 
most parsimonious model is the one that includes resection margin (with narrow margin as 
reference as it is the research variable of interest) and grade (with high grade as reference). 
Given that re-excised wide margin compared to measured wide margin appeared to be significant 
in the univariate analysis a model using re-excised margin as reference was also constructed and 
compared with the full model using narrow margins as a reference. This did not show the re-
excised wide margin to significantly add to the full model. Each variable was subsequently fit 
into a model testing for interaction between it and the main variable of interest (margin status) 
and no significant interaction effects were identified.  
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Table 4.9  Details of the full model of the multivariable logistic regression analysis for local 
recurrence in early stage breast cancer 
Variable Multivariable OR (CI) p value 
Narrow margin vs. wide margin measured .689 (.334-1.423) 0.314
Narrow margin vs. wide margin re-excised 1.576 (.815-3.044) 0.176
Age (less than or equal to 40) 1.736(.672-4.355) 0.24
 Grade 3 vs grade 1 2.832 (1.298-6.178) 0.009
Grade 2 vs grade 3 .607 (.323-1.143) 0.122
Extensive DCIS 1.565 (.608-4.027) 0.353
Positive nodal status 1.393 (.790-2.457) 0.252
Adjuvant chemotherapy or hormonal therapy given 1.478 (.814-2.683) 0.199 
T2 vs T1 tumor size 1.28 (.681-2.406) 0.443
Radiation boost given 1.407 (.640-3.093) 0.395
 
Table 4.10  Results of model building, comparison of the full model to a model with the variable 
in question being removed.  
Variable -2LL Full model -2LL LL Significant 
Size 419.620 418.251 1.369 no 
Age 418.313 418.251 .062 no 
High grade 463.766 418.251 45.515 yes 
Chemo/hormonal therapy 420.040 418.251 1.789 no 
Extensive DCIS 418.865 418.251 .614 no 
Nodal status 418.960 418.251 .709 no 
Radiation boost 418.765 418.251 .514 no 
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4.3.3 Kaplan-Meier Survival Curve 
A Kaplan-Meier survival curve was calculated and is presented in Figure 4.3. This shows no 
statistically significant difference between the narrow and wide margin groups for local 
recurrence.  The follow-up period extended out as long as 20 months.  
Figure 4.3 Kaplan-Meier Curve Demonstrating Length of Time to Recurrence 
 
 98 
 4.3.4 Cox Proportional Hazards Model 
A Cox proportional hazards model was developed using the variables established for the full 
model of the logistic regression analysis. Similar model building techniques as were used in the 
multi-variable analysis were applied to the Cox proportional hazards model analysis. The 
proportional hazards assumption was met as can be seen in figure 4.4. Margin status (narrow 
versus wide) did not significantly predict local recurrence. Grade 3 tumors versus either grade 1 
or 2 is the only variable that significantly predicted for local control with a hazards ratio of 
2.3360 and a confidence interval of 1.3649-3.998.  
Figure 4.4 Cox Proportional Hazards Model showing grade alone predicting local recurrence 
 
The results presented in this chapter, other than the Cox proportionate hazards calculations, 
are also found in the peer reviewed publication of this work in the Journal of Surgical Oncology 
(Appendix A). 
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CHAPTER 5 
 DISCUSSION 
5.1 Introduction 
The NSABP-06 trial, which ushered in a new era of more conservative surgical management 
of early stage breast cancer, was published in 1985.(229) Twenty five years later BCT remains 
one of two primary surgical options for the management of these patients. The problem of local 
recurrence that was identified early on however continues to vex the medical community. The 
significance of a local recurrence in the ipsilateral breast increasingly seems to not only be the 
psychological distress women who have a local recurrence experience and the trade off made in 
the decision making between BCS and a modified radical mastectomy but also a potential for 
decreased survival for those women who have a local recurrence. Therefore finding ways to 
minimize local recurrences in BCT is important. This can be realized in one of three ways. One 
can improve the treatment techniques in order to decrease the incidence of local breast 
recurrence, improve the selection of patients who are a candidate for BCS or find ways to better 
match treatment with the patient—the holy grail of personalized care that we are hearing more 
and more about in the literature.  
As one begins to unwrap these three potential options the complexity of the problem quickly 
becomes apparent. Early stage breast cancer patients treated with BCS typically have three 
treatment modalities applied to the management of their disease, both for local control and for 
the treatment of potential systemic failure and death. While the later has not been the focus of 
this thesis it is clearly of paramount importance not only as the primary objective of treatment 
but also in terms of how it interacts with local control.  
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Radiation therapy has definitively been shown to decrease local recurrence in BCT.(21, 37, 
38, 40-42, 70, 71) In order to treat both the current malignancy and to decrease the occurrence of 
new primary cancers in the ipsilateral breast whole breast irradiation is the standard of care. A 
boost of 16 Gy of radiation to the tumor bed confers a further reduction in local recurrence rates 
but at a cost of increased fibrosis and an accompanying decrease in cosmesis.(72)  
Systemic treatment with either adjuvant chemotherapy or hormonal therapy was offered to 
node positive women early on following the discovery of chemotherapy as a treatment option. 
The early research demonstrated a statistically significant improvement in survival for these 
women. Over the last quarter century the benefits of systemic adjuvant therapy for at least some 
node negative women has been explored and shown to be effective.(230, 231) While it is 
increasingly clear that some node negative women do benefit from systemic adjuvant therapy the 
current challenge for systemic treatment is to be able to identify those node negative women who 
will not derive benefit from systemic adjuvant treatment so as to spare those women the cost of 
going through unnecessary treatment. 
Optimizing surgical management is likewise complex. The question of how much surgery is 
optimal in BCS has been the focus of this thesis. The study conducted for this thesis examining 
the role of a narrow (less than or equal to 2mm) surgical resection margin in local recurrence 
significantly adds to the existing literature in providing information to guide the clinical question 
of whether or not to re-excise lumpectomies with a narrow but negative surgical resection 
margin. A detailed examination of this will occur in the first section.  
It is somewhat surprising that it took 15 years for the literature to recall that a small positive 
effect can be missed in studies that are underpowered with short follow up periods. Stotter et 
al.’s article underscored the need for a large randomized cohort of patients (a minimum of 
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10,0000) comparing BCT with modified radical mastectomy and followed for at least 10 years to 
allow for the survival equivalence claimed by the NSABP-06 and other similar trials to be 
valid.(171) It wasn’t until the Early Breast Cancer Trialist Collaborative Group published a 
meta-analysis of randomized trials in 2005 that the survival equivalence of BCT and modified 
radical mastectomy was examined more carefully.(70) With the results of that met-analysis in 
hand the problem of local recurrence potentially takes on new significance. The question of 
whether every woman with an early stage breast cancer should be an equal candidate for BCS or 
not is no longer just a question of cosmesis and psychological distress but potentially survival as 
well.  
Twenty five years of research examining factors associated with local recurrence in BCS has 
provided much illumination. We know for instance that women of young age, high tumor grade, 
lymphovascular invasion etc. are at increased risk of local recurrence. We do not, for the most 
part, have adequate focus of that illumination however to make use of the information to direct 
patient care. Ideally we would have markers of one sort or another that individually, or as a set, 
would allow for the selection of the small cohort of women who will have a local recurrence if 
submitted to BCS so that they might be directed appropriately to a mastectomy in the first 
instance. Chapter 7 will explore further avenues of research that might help in this regard.  
In attempting to realize the goal of personalized care in breast cancer one must acknowledge 
just how far we really are in achieving that goal. The first of the “targeted” therapies for cancer 
was directed at the epidermal growth factor receptor (EGFR). Monoclonal antibodies directed at 
that receptor have been developed and brought into clinical practice.(232) Imatinib is a 
derivative of 2-phenylaminopyrimidine that selectively inhibits the tyrosine kinase receptor. This 
drug was initially developed for the specific inhibition of the fusion gene product BCR-ABL 
 102 
found in chronic myelogenus leukemia.(233) In 2001 Imatinib was used for a patient with a 
gastrointestinal stromal tumor with a significant response.(234) Subsequent success in 
discovering the Her2 receptor and it’s targeted therapy Trastuzumab in breast cancer and the 
development of targeted therapies to vascular endothelial growth factor (VEGF), mesenchymal-
epithelial transition factor (C-MET), and Src, insulin-like growth factor-1 receptor (IGF-1R), has 
fuelled the initial enthusiasm and excitement brought about by molecular targeted therapy.  
The reality is that these targeted therapies are applicable to a very small subset of cancers. 
With few exceptions these therapies as a group have limited application outside of the metastatic 
palliative arena. It is important—imperative actually—to step back from the busyness of 
answering highly focused research questions emanating from urgent and pressing clinical 
problems to ask if we are asking the right questions in the first place. In returning to theory and 
examining the assumptions that are brought to the table it is hoped that new ideas and research 
questions can be found. 
 
5.2 Surgical Resection Margin as a Variable to Control in Limiting Local Recurrence in 
Early Stage Breast Cancer Treated with BCT. 
5.2.1 Overview 
The study done for this thesis shows that a narrow but negative surgical resection margin in 
stage I and II invasive duct carcinoma treated with BCT does not result in a greater likelihood of 
local recurrence compared with wider resection margins (either wider margins by measurement 
combined with re-excised wider margins, wider margin by measurement alone, or wider margin 
by re-excision alone). It would follow that re-excision of narrow margin segmental resections is 
therefore unwarranted.  
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That would seem to be a bold statement to make following a single retrospective study. To 
assess the validity of that statement it is important to take a closer look at the whole issue of 
causal inference in research studies. Much has been written about causality and inference in 
research, an issue that continues to be revisited intermittently and is an ongoing issue that the 
health science research community needs to be aware of.  
5.2.2  Definition of Causal Inference  
Kenneth J. Rothman uses a light switch as an example of how we think about causation in 
general.(235) When a light switch is turned to the on position a light comes on and when it is 
turned to the off position that same light turns off. After seeing that association replay itself time 
and again over many days and weeks it is easy to draw the conclusion that the causal mechanism 
for getting a light to shine is the light switch. Of course the complete causal mechanism is much 
more intricate and the switch is only one component of several. Because the switch is the only 
part of the whole mechanism that needs to be activated to obtain the effect of turning on the light 
we tend to focus on it as the cause, ignoring the wiring for example. Only when the power goes 
out in a storm or the light bulb burns out do we consider the other factors (at least some of them).  
Parascandola and Weed explore the concept of causation in epidemiology and offer several 
useful insights.(236) An indepth review of the literature revealed five different ways that cause is 
defined.  
The first of these definitions they call production definitions. Under this definition a cause is 
something that creates or produces an effect. They point out that this definition is vague, leaving 
the concepts of production and creation undefined and as a result suggest that a more robust 
definition is required.  
Necessary and sufficient cause definitions are commonly presented in epidemiology.  
Classical epidemiologic teaching suggests that there are four types of causal relationships, 
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necessary and sufficient, necessary and not sufficient, sufficient but not necessary and neither 
sufficient nor necessary. A factor is both necessary and sufficient when the disease in question 
never develops without that factor and in the presence of that factor the disease always develops. 
In practice this almost never occurs. Some genetic anomalies such as Down’s syndrome would 
be an excellent example. A factor is consider to be necessary but not sufficient when it is 
required for a disease to occur but by itself is not sufficient to cause the disease. Infectious 
diseases are a good example of this as the infection cannot occur without the bacteria in question 
but not everyone exposed to said bacteria develops the illness in question. With sufficient but not 
necessary factors there are more than one factor that can cause a disease independently of one 
another. The criterion of sufficient is difficult to fill even for one factor let alone more working 
totally independently of each other. It is unlikely that this type of causal relationship is 
encountered very often. The neither sufficient nor necessary model probably reflects reality the 
most. This complex model envisions a complex interplay between factors that ultimately cause a 
particular disease. Moreover it envisions more than one possible combination of factors that 
might explain the cause of a given disease.  
Sufficient component cause definition of causation was articulated by Rothman. Under this 
perspective cause is made up of a number of components, no one of which is sufficient for the 
disease on its own. When all of the components are present however a sufficient cause is formed. 
They take issue with this definition as well arguing that “the sufficient-component cause 
definition requires that we assume the existence of countless hidden effect modifiers to turn 
every less than perfect correlation into pure determinism”.  
A probabilistic or statistical definition of causation forms the fourth type of definition. Under 
this definition cause is defined as the probability of a disease occurring in an individual exposed 
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to a given factor. They felt that this type of definition offered the greatest range of possible 
effects and allows for the possibility that other undiscovered causes may also be at work. They 
express concern that probabilistic definitions remain unclear about what it means for a factor to 
increase the likelihood of a disease. Cox, Holland and Olsen take exception to his kind of 
definition arguing that it is not possible to draw a distinction between causal relations and non-
causal associations. Parascandola and Weed make the counter argument that adding a 
counterfactual element to the definition meets this concern.  
A counterfactual statement draws a contrast between one outcome given certain conditions 
and another outcome given alternative conditions and some statisticians and epidemiologists 
advocate a definition base on this concept. Counterfactual statements can be either deterministic 
or probabilistic. Parascandola and Weed argue that “counterfactuals articulate an additional 
attribute that we suspect will enhance any definition of causation by strengthening the distinction 
between causation and mere correlation” but go on to dismiss it as a sufficient definition in its 
own right.  
In summary Parascandola and Weed argue for a probabilistic definition of causation 
combined with a counterfactual condition as the most useful definition.  
5.2.3 Study Design and Causal Inference 
5.2.3.1 Overview 
Experimental designs have traditionally been classified as true experimental, quasi-
experimental, pre-experimental and nonexperimental with the true experimental design being the 
criterion by which all other metholologies are judged.(237) It is this experimental design that is 
used most often to reveal causal relationships and is held up with the highest regard in 
determining evidence based practice and developing clinical practice guidelines. True 
experimental designs are characterized by the prospective randomized study in which subjects 
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are randomly assigned to either an experimental or control group. Three elements of a true 
experimental design are random assignment, a control group and manipulation. In health 
research experimental designs are not always possible, appropriate or ethical in which case 
quasi-experimental designs are the next best option. In these study designs randomization is 
absent. Because of the lack of random assignment one needs to more careful in making causal 
claims, assuring that alternative explanations are considered and the limitations of the study 
design acknowledged. In pre-experimental designs, in which two of the three criteria of true 
experimental design are absent, and nonexperimental designs which rely on statistical 
manipulation of data rather than mechanical manipulation and sequencing causal inference 
should be avoided.  
5.2.3.2 Deriving inferences from epidemiologic studies 
The first thing that one does in a study is establish whether or not there is an association 
between a factor and a disease.(238) Does treatment A work or not, does this exposure result in 
disease or not, or in the case of this thesis work does a narrow surgical resection margin in BCT 
for early stage breast cancer result in an increased incidence of local recurrence or not. Relative 
risk and the odds ratio are two measures of association that are used. Relative risk is the ratio of 
the risk of disease in exposed individuals to the risk of disease in nonexposed individuals. In 
case-control studies the only measure of association is the odds ratio whereas in cohort studies 
both relative risk and odds ratio can be valid measures of association. In cohort studies the odds 
ratio is defined as the ratio of the odds of development of disease in exposed persons to the odds 
of development of disease in nonexposed persons. In case control studies the odds ratio the ratio 
of the odds that the cases were exposed to the odds that the controls were exposed.  
Once an association is identified between a factor and an outcome the next question is 
whether or not that association is a result of a causal relationship. The failure to be clear about 
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the difference between association and causality costs the collective research endeavor 
significantly. Gary Taubes explores this problem in an article entitled “epidemiology faces its 
limits”.(239) From his article it is evident that the chiasm between association and causation is 
exacerbated by the media  (which he describes as the unholy alliance) but a significant onus must 
be placed on researchers to understand the limitations of the studies they perform. In his article 
Taubes offers some practical suggestions about when to take a study seriously. He suggests that a 
combination of a very strong association between a disease and risk factor along with a highly 
plausible biological mechanism should be present. He goes on to suggest that no single 
epidemiologic study is persuasive by itself unless the lower limit of its 95% confidence level 
falls above a three or even four fold risk increase. Consistency is another factor to be considered 
but is only valuable if the studies use different architectures, methodologies and subject groups 
and still comes up with the same results.  
Hill articulated a set of criteria to aid in making causal inference that are still in frequent use 
today.(240) These criteria are strength of the association, consistency, specificity, temporality, 
biological gradient, plausibility, coherence, experimental evidence and analogy. Hill himself and 
others since have some degree of ambivalence about using a set of criteria like this to pass 
judgement on when an observed association can be assigned a verdict of causation because its 
checklist nature risks clouding the logical deductive thought process required to make that 
assessment.  
5.2.3.3 Levels of evidence 
Evidence based medicine is by now a commonly articulated concept. Because clinicians need 
to be able to translate research to the bedside they have had to develop some sort of framework 
under which they can make recommendations in the common situations where research evidence 
falls short of being conclusive. The University of Oxford center for evidence based medicine has 
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a table that provides the reader easy access to the framework and how it works (Appendix 
B).(241) It incorporates the principles espoused by Hill in 1965 and attempts to fit them into a 
framework that can be used on a clinical level.  
5.2.4 Review of existing literature. 
 The existing literature addressing the subject of local recurrence in stage I and II breast 
cancer treated with BCT was grouped according to the type of experimental design. This is 
presented in Table 5.1  Four of the articles reviewed were not included. Two of these (Freedman 
et al. and Fredrikson et al.) were excluded because it was unclear what a narrow margin was, one 
(Chism et al.) because there was no comparison to a wider resection margin group, and the fourth 
(Vordemark et al.) because their definition of a narrow margin (4 mm.) was so widely divergent 
from the rest of the literature. With the exception of one study these are all non-experimental 
studies in which a data set from a cohort of patients underwent statistical interrogation, usually 
with a logistic regression model or multivariate analysis looking to see if there were any 
variables that were predictive of local recurrence. There was only one case-control study in this 
group, the one conducted by Hardy et al.  
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Table 5.1 Study design in narrow margin studies  
Study Experimental Quasi-experimental Non-experimental 
Schnitt et al.   Yes 
Gage et al.   Yes 
Touboul et al.   Yes 
Freedman et al.   Yes 
Pederson et al.   Yes 
Park et al.   Yes 
Perez et al. 2003/2010   Yes 
Fredrikson et al.   Yes 
Smitt et al. 1995/2003   Yes 
Chism et al.   Yes 
Kunos et al.   Yes 
Bollet et al.   Yes 
Hardy et al.  Yes  
Jones et al.   Yes 
Perez et al.   Yes 
Vordermark et al.   Yes 
Goldstein et al.   Yes 
Karasawa et al.   Yes 
Wazer et al.   Yes 
Pittinger et al.   Yes 
Solin et al.   Yes 
 
Table 5.2 provides an overview of these studies including the number of patients in the study, 
the number of narrow margin patients and the association between local recurrence and narrow 
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margins found by the study. Of note the two publications by Smitt et al. and Parez et al. are on 
the same data set but at different dates.  
Table 5.2 Narrow vs. wide margin study details 
Study  Number of 
patients 
Number of narrow 
margin patients 
Association with local 
recurrence 
Schnitt et al. 181 25 No 
Gage et al. 343 54 No 
Touboul et al. 528 21 No 
Pederson et al. 1.021 96 No 
Park et al. 533 94 No 
Perez et al. 2003 1037 56 No 
Smitt et al. 2003 535 55 Yes 
Kunos et al.  341 22 Yes 
Bollet et al.  209 42 No 
Hardy et al.  200 52 No 
Jones et al.  1616 306 No 
Perez et al. 2010 1521  No 
Goldstein et al. 607 231 No 
Karasawa et al. 941 326 No 
Wazer et al. 509 99 No 
Smitt et al. 1995 303 17 Yes 
Pittinger et al. 211 35 No 
Solin et al. 697 35 No 
 
It is clear from the literature compiled to date that the association between local recurrence 
and narrow surgical resection margins in early stage breast cancer treated with BCT cannot be 
considered causal. Almost without exception the quality of the study design was non 
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experimental and as such does not allow for causal inference. Only two studies showed an 
association between narrow surgical resection margins and local recurrence (one published twice 
at different time periods). The one case control study available showed no statistical difference 
between narrow margin groups and wider surgical resection margins. It is disturbing therefore to 
see authors making statements such as, “it is well established that the extent of surgical resection 
at the time of BCS influences the risk of local-regional breast cancer recurrence” or “although 
much debated, 2 mm tumor-free margins have been associated with fewer local-regional breast 
cancer recurrences after BCS”.(152) While these statements are technically true in the sense that 
positive surgical resection margins (particularly grossly positive margins) are strongly associated 
with local recurrence and there have been two publications that have found an association 
between a surgical resection margin of less than 2 mm and local recurrence these statements 
were made in a manner and context that ignore alternate studies and strongly imply a causative 
interference.  
5.2.5 Current Study 
5.2.5.1 Study design 
This study was a retrospective cohort study. As mentioned in the methodology section of the 
study it was considered impossible to conduct a randomized prospective study for this particular 
research question (one could not randomly assign women to a narrow or wide resection 
margin—apart from the obvious technical difficulty surgeons would encounter in assuring the 
person in front of them received the required margin that study design would not be ethical). 
Conceptually one could prospectively follow all stage I and II patients who had BCS and divide 
them according to margin of resection and then follow them for evidence of local recurrence for 
10 years. Those with narrow surgical resections could even be randomly assigned to re-excision 
or not. Because of time constraints inherent with such a prospective study and difficulty 
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anticipated in randomizing the narrow margin lumpectomy patients given the current practice 
guideline recommendations it was decided to use the next best study design—a retrospective 
cohort design. This study design, which is quasi-experimental, can allow for causal inference 
although one needs to be more careful assuring that alternative explanations are explored and 
limitations acknowledged.  
5.2.5.2 Power and sample size 
One of the concerns that has not yet been discussed is that of study size and power. Sample 
size calculations are used in both experimental study designs and quasi-experimental study 
designs.(237) There are four possibilities to consider when interpreting a study finding. There is 
no association and the study correctly identifies that, there is no association but the study 
incorrectly identifies one, there is an association and the study correctly identifies that 
association or there is an association but the study fails to identify it. Power has been defined as 
the probability of detecting a difference between two treatments (or in this case narrow and wide 
margins) if the treatments do in fact differ.(238) The number of patients that need to be enrolled 
to assure that a negative association is real (and avoid a Type II error) can be calculated. This 
requires knowledge of the difference in response rates to be detected (a variable which should be 
clinically significant), an estimate of the response rate in one of the groups, a level of statistical 
significance or alpha (often .05), the value of the power desired or beta (frequently 0.8) and 
whether the test should be one or two sided. In this study the sample size calculation for a two 
sided test, alpha of .05, beta of 0.2 an anticipated difference in local control of 50% and a local 
recurrence rate in wide excisions of 10% in 10 years revealed that each arm of the study (narrow 
vs. wide resection) would require 200 patients. That was achieved making this the only study in 
the literature that is adequately powered to answer the question of whether or not a narrow 
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surgical resection margin in early breast cancer patients treated with BCT results in an increase 
in local recurrence.  
5.2.5.3 Hill criteria 
Acknowledging the limitations of using a set of criteria for causal inference it is still worth 
examining this study in that light. This study will be examined from the perspective of each of 
the nine Hill criteria.(238, 240) 
The first criterion is that of temporal relationship. Clearly for a factor to cause a disease 
state exposure to that factor must have occurred before the disease developed.  It is evident that 
this criterion has been met in so much as any local recurrence occurs after the initial treatment 
has been completed.  
The second criterion is that of the strength of the association. In this study there was no 
association noted between local recurrence and narrow resection margins.  
The third criterion is that there is a dose-response relationship. If there was an association 
between the extent of surgical resection margin and local recurrence it would be logical that 
there would be some form of dose-response relationship, ie. the greater the margin of resection 
the less the local recurrence rate. In fact there are some who advocate wider and wider margins 
based on the assumption that such a relationship exists. One study examined in the literature 
review demonstrated an association between local recurrence and tumor volume near the 
resected margin. This one study, more so than the various re-excision studies, lends credence to 
some sort of dose-response curve but has not been validated in other studies. The extreme end of 
this position in fact would be a return to a mastectomy as the standard of care, which is unlikely 
to be accepted. There is adequate evidence to demonstrate an increasing range of local 
recurrence between grossly positive and focally positive lumpectomy specimens treated with 
BCS supported by re-excision data that shows greater residual cancer in grossly positive re-
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excised lumpectomy specimens compared with focally positive re-excised lumpectomy 
specimens. It is a large step in logic to assume that a continuum exists from there to closely 
excised lumpectomies. Especially given that during the time frame of this and many of the 
studies in the literature a lumpectomy was often both a diagnostic and therapeutic tool (as 
opposed to the current practice where a core biopsy confirms the diagnosis most of the time in 
advance of the lumpectomy). Given that only about 20% of all wire guided biopsies were 
positive for cancer it was not that unusual for a lumpectomy to cut through tumor and result in a 
positive margin. In those cases the surgeon was intending to have a further discussion with the 
patient and plan further surgery based on that discussion. The continuum argument can only be 
considered if the initial lumpectomy specimen was always intended to be therapeutic.  
Replication of findings is the fourth criteria. Even amongst the non-experimental studies the 
vast majority do not show a difference in local recurrence between narrow surgical resection 
margins and wider ones so long as there was no tumor at the inked resection margin.  
Biological plausibility is the fifth of Hill’s criteria. The fact that positive margins were 
clearly associated with an increased local recurrence combined with the re-excision studies 
demonstrating residual tumor in specimens that initially had a surgical resection margin less than 
or equal to 2 mm. undoubtedly was the impetus for the hypothesis that narrow margins might be 
associated with an increase in local recurrence. This hypothesis fails to take into consideration 
that BCT includes adjuvant radiation therapy. The appropriate question to ask is what is the 
amount of breast tissue that one has to remove that will allow for the adjuvant radiation treatment 
to deal with the residual tumor burden.  
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Consideration of alternate explanations and cessation of exposure and specificity of 
association, Hill’s sixth and seventh and ninth criteria, are not applicable as there is no 
association noted.  
Consistency with other knowledge while an important criterion that is worth exploring there 
is no other information that can be brought to bear on the subject that gives further illumination. 
5.2.5.4 Study strengths 
There are several strengths of this study above and beyond the study design and power issues 
discussed already.  All histology other than invasive duct carcinoma were excluded, allowing us 
to confidently say that we are comparing like cases. Schwartz’s textbook of surgery says that 
only 80% of all breast cancers are infiltrating duct carcinomas with the remainder largely being 
better prognosis tumors.  All cases where the original pathology was not measured or a re-
excision carried out with no residual tumor underwent independent pathologic review. There 
were almost no cases lost to follow-up. A multivariable regression analysis took into 
consideration other variables that have been associated with local recurrence.  
5.2.5.5 Study limitations 
The limitations of this study are primarily those inherent to a retrospective cohort study.  In 
addition the single institutional nature of this study should be considered a limitation.  
Specifically, the pathologic review was limited to those cases where the margins could not be 
determined due to the practicality and cost of conducting a pathologic review of all cases. Other 
than margin status itself the limited pathologic review could have an impact on two other 
pathologic issues. Both of these issues could be of significant importance. First of these is the 
histologic type. There are distinct histologic categories that are in current practice that were not 
recognized during the timeframe that this study was conducted—particularly the triple negative 
or basaloid tumor (which is in reality a hybrid of histologic characteristics frequently found in 
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one of the genetic classifications) and the micropapillary tumor. Both of these are associated 
with a poorer prognosis. While uncommon we do not know the distribution of these two tumor 
histologies between the groups. Second, the presence or absence of DCIS and its extent  
(variables associated with local recurrence), may not be accurately categorized. In our study 
614/825 (74.4%) of the cases had no mention of DCIS, 151/825 (18.3%) had focal DCIS, and 
60/825 (7.3%) had extensive DCIS recorded. Prior to 1998 it was not routine to report the extent 
of DCIS in the pathology report. Moreover the presence and extent of DCIS at the tumor 
resection margin was not routinely reported and is a variable that was not considered in this 
study.  
It is noted that the local recurrence rate in this study is higher than is seen in some current 
series. The literature shows a local recurrence rate with BCT to range from 3 to 20%.(61, 84, 
191)  In the study period used there was limited use of radiation boost (126/825 or 15.3%), 
which has since been demonstrated to decrease local recurrence significantly(72). Likewise 
literature shows that chemotherapy use is associated with a lower incidence of local recurrence 
(70, 230, 231) and the use of chemotherapy in the study period was lower than is current practice 
(only 377 or 45.7% of the entire group had some form of chemotherapy or hormonal therapy). 
Furthermore the follow-up in this study is a minimum of 10 years, which is significantly longer 
than most series. Local recurrence has been shown to continue to increase over time. A study 
with a longer follow-up period would be expected to have a higher local recurrence rate. These 
factors combined likely contribute to explaining the higher rate of local recurrence identified in 
this series compared with the current reality.  
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During the study period compression of wire guided specimens in diagnostic imaging were 
routinely performed, a practice that is no longer the case at least in Saskatoon. The extent to 
which these compressions distorted the surgical margin is unclear.  
5.2.5.5 Evidence based medicine perspective 
Prior to this study the level of evidence for the question of whether or not a narrow surgical 
resection margin is associated with an increase in local recurrence was level 4 (case-series and 
poor quality cohort or case-control studies). This retrospective cohort study elevates that to Level 
3b 
5.2.5.6 The “why not re-excise” argument 
The suggestion made by some that, in the absence of convincing evidence to the contrary, one 
should do whatever possible to avoid local recurrence deserves attention. While not explicitly 
stated this opinion likely explains in the wide range of what practitioners consider to be an 
acceptable surgical resection margin in BCT done for early stage breast cancer.(61, 242)  
Given that there is evidence that microscopic malignancy is left behind when a surgical 
resection margin is negative but less than or equal to 2 mm it might be tempting to suggest that 
this subgroup should have the “do more if in doubt” adage applied. To do so without 
consideration of the costs of that action fails to consider all facets of the decision being made. 
Not only are there clear physiological and financial costs to doing so the study done for this 
thesis raises the possibility that re-excision for a narrow margin might actually be associated with 
a greater risk of local recurrence, the exact opposite of what it is hoping to achieve.  This study 
was not designed to address this unexpected finding but it is not the first time the possibility has 
been considered. In 1985 Papaioannou entertained the hypothesis that increasingly intensive 
locoregional treatment of breast cancer may promote recurrence through a variety of local, 
regional and systemic tumor-promoting mechanisms.(243) Menes et al. concluded that  “the risk 
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of local recurrence after breast conservation for breast cancer increases progressively with the 
number of re-excisions needed to achieve clear margins” while O’Sullivan et al concluded 
exactly the opposite.(163, 164) There are several possible explanations for the observation made 
in this study. It is possible that there is a selection bias (surgeons selected cases more likely to 
recur locally for re-excision), there might be something negative about re-excision that makes 
local recurrence more likely (change in the local environment that makes radiation less effective, 
spread of tumor cells or poor orientation at the first surgery with a result of the re-excision being 
inadequate) or re-excision results in a delay in receiving adjuvant radiation which in turn results 
in an increase in local recurrence. The variables included in our multivariable analysis do not 
identify a particular variable that might have contributed to selection bias but does not eliminate 
this as a possibility. A delay in receiving adjuvant therapy is variably associated with increased 
local recurrence rates.(74, 78, 120) Therefore, time to receiving adjuvant therapy was added into 
the multivariable full model to assess this possibility. Time to treatment using cut offs of 6, 8, 10 
or 12 weeks did not significantly affect local recurrence in any of the margin groupings.  
5.2.5.7 Local recurrence rates—are they changing? 
There is evidence that local recurrence rates are declining, likely for a variety of reasons.(244) 
The five year local recurrence rate in a recently published study of women treated with BCT 
between 1998 and 2002 showed a local recurrence rate of 3.1%. Earlier studies demonstrated 
local recurrence rates more in the 8% range. If this observation is true it is worth considering 
why that might be. There has been some speculation (and evidence) that the decrease in local 
recurrence rates can at least partially be attributed to the increase in specialization, with more 
patients receiving what is considered to be the standard of care.(244) An examination of the 
United States Surveillance Epidemiology and End Results (SEER) population based data shows 
that the proportion of women over the age of 65 with a diagnosis of breast cancer has gone from 
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37% in 1973 to 46.7% in 1995.(244) Older age is known to be associated with a better prognosis 
both in terms of survival and in terms of local recurrence in BCT. Therefore, even though the 
mechanism for the age association is not completely clear, one can anticipate this increasing age 
demographic alone to result in a decrease in the overall incidence of local recurrence in more 
current series of women undergoing BCT in early stage breast cancer. It is now common practice 
to treat node negative women with early stage breast cancer with systemic adjuvant therapy, 
either with endocrine therapy or cytotoxic chemotherapy. This was not the case during the time 
period of the study conducted for this thesis. In 1992 the Early Breast Cancer Trialist’s 
Collaborative Group (EBCTCG) published a systematic overview of adjuvant systemic 
therapy.(230) Subsequent to that an international conference on adjuvant therapy of primary 
breast cancer was held. The recommendation coming out of that conference was that “almost all 
patients with clinical and pathologic stage I and II breast cancer, regardless of age, menopausal, 
nodal, or receptor status, will benefit from some form of adjuvant chemotherapy and /or 
hormonal therapy both in terms of improved disease-free, as well as overall survival.(231) 
Tamoxifen daily for five years reduces local recurrence risk by about 50% in estrogen receptor 
positive patients. (70)This benefit is extended to post-menopausal women with the addition of 
aromatase inhibitors.(245) Chemotherapy reduces the risk of local recurrence by about 30%, a 
benefit that is age-dependent being higher in younger women.(70) Trastuzumab has been shown 
to reduce local recurrence in Her2 positive women.(246, 247) Moreover, as mentioned earlier, 
the addition of a boost of radiation to the tumor bed has been shown to reduce local recurrence in 
early stage breast cancer treated with BCT.(72)  
5.2.5.8 Conclusion 
Returning to the question posed at the beginning of this section of whether or not it is 
reasonable to conclude that the re-excision of lumpectomy in which there is a surgical resection 
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margin less than or equal to 2mm is unwarranted in breast conserving surgery one must consider 
all of the above discussion. Of the twenty-two articles in the literature there are none that are of 
an experimental design. After removing the four articles that were excluded from the review only 
one was of a quasi-experimental design, the case-control study by Hardy that was underpowered. 
Of the remaining seventeen pre-experimental studies the vast majority did not show an 
association between a narrow surgical resection margin and local recurrence in early stage breast 
cancer treated with BCT. Of those that did, one was the same data set reviewed at different 
points in time and all had methodological concerns (see literature review). The study conducted 
for this thesis adds the only quasi-experimental study looking at the role of narrow surgical 
resection margins in local recurrence amongst women with stage I and II breast cancer treated 
with BCT that is adequately powered to address the question fully. From an evidence based 
medicine perspective this study elevates the level of evidence that narrow margin lumpectomies 
do not require re-excision to level 3 evidence. In the absence of a high level of evidence other 
information needs to be considered in making a decision. Clearly the treatment of early staged 
breast cancer has changed since patients included in the study conducted for this thesis 
underwent their cancer treatment. Few of the cohort studied were offered a boost of radiation to 
the tumor bed and a relatively small percentage of them were given adjuvant systemic treatment, 
two important treatment options in common practice today. Finally, the observation that the 
group who had a wide margin by virtue of a re-excision raises the possibility that re-excision 
might even be negative with regards to local recurrence in early stage breast cancer. While it is 
freely accepted that this study does not address this in a manner that can be anything other than 
an observation, there is recent evidence that makes this observation plausible. Demicheli et al. 
address the implied (almost never articulated) theoretical basis for the observed beneficial effect 
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of adjuvant radiation.(248) They examine the current theory that radiation’s beneficial effect is 
derived from direct tumor cell death in light of the evidence and conclude “the beneficial effect 
of RT could be attributed not only to tumour cell killing but also, and probably more importantly, 
to its ability to modify the wound microenvironment, making it less favourable for cancer cell 
growth and invasion”. Their observations are congruent with the emerging theories of 
oncogenesis reviewed earlier. In particular the cancer stem cell theory and the tissue 
organizational field theory (TOFT) have in common concepts about the tumor micro-
environment.  
In view of all of the above it is more than reasonable to assert that the current retrospective 
cohort study in the context of the current environment of care provided to stage I and II breast 
cancer patients offers enough evidence to end the current practice of re-excision of negative but 
narrow (less than or equal to 2 mm) surgical resection margin in these patients. Not only do such 
re-excision not offer any obvious advantage from a local recurrence perspective they could 
potentially be deleterious.  
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CHAPTER 6 
CONCLUSIONS 
In conclusion this retrospective cohort study confirms that a narrow (less than or equal to 2 
mm) surgical resection margin in early stage invasive duct carcinoma treated with breast 
conserving therapy does not result in an increase in local recurrence over a minimum 10 year 
follow-up and therefore does not warrant re-excision.  
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CHAPTER 7 
FUTURE DIRECTIONS 
 
7.1 Overview 
 
Personalized care is considered by many to be the future of cancer care. The “holy grail” of 
personalized cancer care is to have the ability to predict who will benefit the most from which 
treatment. In the case of local treatment the desire would be to perform breast conserving surgery 
on those women who will not have problems with local recurrence and to perform a mastectomy 
on those who will. With a 6-10% local recurrence rate over 10 years in early stage breast cancer 
treated with BCT it is clear that our ability to accurately predict who needs which surgical 
treatment has still not been achieved. In fact the only exclusion criteria currently applied to the 
decision making around BCS is documented multifocality, large tumors in a women with a small 
breasts, inflammatory cancer and advanced carcinomas—for everyone else BCT is considered 
the standard of care despite the know local recurrence rate and potential for it to impact survival.   
In the absence of clear predictive markers to guide practitioners in choosing who should have 
BCT and who should have a mastectomy one must ask if there is anything that might give the 
medical community that kind of knowledge in the future.  
7.2 Genomic prediction 
7.2.1 Introduction 
Increasingly it is understood that cancer is not one heterogeneous disease making it probable 
that the tools that have been traditionally used to prognosticate, such as surgical margins, grading 
systems etc., may be inadequate to predict outcome. Molecular options of examining tumors 
have opened the possibility of a more accurate modality of prognostication. 
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7.2.2 DNA microarray and local recurrence 
Gene expression profiles have captured the imagination of the cancer research community 
with the hope of being able to better select patients for care based on the genetic profile their 
particular tumor.  In terms of this new modality’s role in predicting local recurrence there have 
only been four publications to date. In 2006 Cheng et al. published a study whose purpose was to 
explore gene expression profiles that are associated with locoregional recurrence in breast cancer 
after mastectomy.(249) They concluded that gene expression profiles do predict for locoregional 
recurrence and can be used to select patients for post mastectomy radiation therapy. In the same 
year Nuyten et al. published a paper indicating that gene expression profiling can identify 
subgroups of patients at increased risk of developing a local recurrence after breast-conserving 
therapy.(250) Ignatiadis and Desmedt offer their opinion that genomic profiling in combination 
with clinicopathologic parameters will be able to discern more accurately those who will recur 
but does not move that hope any closer to reality.(251) Most recently Nimeus-Malmstrom et al. 
report a “highly distinct gene expression profile from patients developing local recurrence after 
breast-conservation surgery despite radiotherapy.”(252) Undoubtedly there will be further 
reports in the literature in the future that will clarify the role of gene expression profiling in 
predicting local recurrence in early stage breast cancer patients with a view to helping make the 
decision of whether to consider BCS or not. 
7.2.3 MiRNA and local recurrence 
7.2.3.1 Introduction 
MicroRNA (miRNA) analysis of tumors is a more recent molecular test that is more useful for 
paraffin embedded tissue samples that have been stored for longer periods of time. The 
possibility that miRNA techniques might provide predictive and prognostic information 
regarding local recurrence in early stage breast cancer, thus allowing for retrospective studies to 
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be performed on tissue samples that have been stored for years, was explored in a pilot study 
conducted as a “future directions” component this thesis work.  
 miRNAs are small, non-coding RNA molecules, involved in post-transcriptional gene 
regulation.(218)  They have been found to be more stable than messenger RNA (miRNA) in 
FFPE tissues.  It is thought that given the size and stability of miRNAs, they are less affected by 
autolysis, cross-linking and fragmentation that occurs with DNA and miRNA during formalin 
fixation and storage.(253, 254) Previous studies have shown that miRNA in FFPE samples in 
colorectal cancer dating back ten years remain stable over that time frame and provide promising 
targets for research into cancer biomarkers.(254)   
miRNAs are typically 21-23 nucleotides in length and function through the translational 
inhibition or degradation of miRNA within the cytoplasm.(255) This is accomplished by 
complimentary binding of the miRNAs to the 3’ untranslated region of the target miRNA in a 
ribonucleoprotein complex known as the RNA-induced silence complex (RISC).  Depending on 
the degree of base pairing, the target miRNA will either be degraded, if tightly bound, or protein 
synthesis will be impaired, if loosely bound. Each miRNA is capable of targeting approximately 
200 different miRNA s and potentially one third of human miRNA s may be regulated in such a 
manner.(256)  
miRNAs regulate various cell cycle processes, and as such can act in both an oncogenic or 
tumor suppressor role depending on the genes targeted.(257) In breast cancer miRNAs have been 
shown to be involved in self renewal, tumorigenicity, invasion and metastasis.(258-261) The 
impact of miRNAs on breast cancer local recurrence has yet to be studied.   
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7.2.3.2 Study question 
The question being addressed by this study was whether or not miRNA microarray analysis 
will contribute in a meaningful way to the prediction of local recurrence in early stage breast 
cancer treated with BCT. The attraction of this technology is that miRNA have significantly 
greater stability in FFPE tissue samples. Because of this miRNA microarray analysis can be 
performed on FFPE samples that have been in storage for a long enough period of time. 
Consequently quick results can be achieved unlike DNA microarray studies, which need to be 
conducted more or less prospectively given the instability of the samples in FFPE tissue.  
7.2.3.3 Study objectives 
Given the very early stages of research with this modality the primary question of the utility 
of miRNA microarray analysis was broken down into three questions. The first of these was to 
determine whether or not FFPE tissue samples that have been stored for 10 years or longer are 
still useful. The second question was if a miRNA profile emerged as a candidate for further 
study. Finally, even though the study was conducted using a very small sample size it was 
thought worthwhile to see if a miRNA emerged that might predict local recurrence in early stage 
breast cancer treated with BCT.  
7.2.3.4 Hypothesis 
The hypothesis is that miRNA microarray analysis has potential as a research tool that might 
lead to the identification of candidate miRNA, which might in turn be predictive of local 
recurrence in early stage breast cancer. 
7.2.3.5 The study design 
A small convenience sample of 4 locally recurrent specimens and 4 non-recurrent 
specimens from the larger cohort that comprised the local recurrence in early stage breast 
carcinoma with narrow margin study was chosen for analysis. The details of the patient 
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characteristics of these eight patients are presented in table 7.1. Tissue blocks that had an 
adequate amount of tumor in the paraffin embedded block were selected in order to ensure 
adequate tumor sampling. Sample age varied from ten to fourteen years. These eight specimens 
were then be subjected to a hierarchical miRNA micro array analysis.  
Table 7.1 Details of cases examined 
ID LR DATE OF DX # NODES SIZE MARGIN ER PR 
1 no Aug-99 0 3 cm narrow + + 
2 no Sep-97 0 1.2 cm narrow + + 
3 no Oct-00 0 2.3 cm wide + + 
4 yes Jun-00 9 4 cm narrow + + 
5 no May-99 0 1.5 cm narrow + + 
6 yes Mar-95 0 1.3 cm narrow + + 
7 yes Nov-96 3 1.6 cm narrow + + 
8 yes Aug-96 2 2.5 cm wide + + 
 
Two one millimeter core sections of tumor were obtained from each of eight FFPE tissue 
samples. In order to assure that the core samples contain malignant tissue a single H&E slide was 
cut and the tumor outlined on the slide by an expert breast pathologist. The cores were taken 
from tissue outlined on the H&E slide.    
The first piece of information that was determined was the amount of intact miRNA 
extracted from the core biopsies. Given the age of the samples it was important to assess whether 
or not the tissue sampled has enough intact miRNA. Total RNA was isolated from the FFPE 
samples using the RecoverAll Total Nucleic Acid Isolation kit (Ambion, Austin, TX) according 
to the manufacturer’s instructions.(253) Agilent MicroRNA V3 arrays, which detect 866 human 
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miRs, was used for profiling.  For each sample the cores were deparaffined with xylene, washed 
twice with ethanol and digested with protease at 50 qC for three hours.  The lysate was then 
passed through a filter cartridge and the RNA eluted in 60 Pl water. The amount of RNA protein 
was diluted so that each of the eight samples contains about 50 nanograms per milliliter of 
solution.  The total RNA amount was assessed for purity using spectrophotometry.   
After assuring that there was adequate miRNA for assessment the next part of the study was 
to perform a supervised and unsupervised hierarchical clustering analysis using microarray 
technology. A microarray is an orderly array of miRNA attached to a solid support. In this study 
866 know human miRNA were used in the array. The miRNAs were labeled using the Agilent 
miRNA complete labeling and hybridisation kit.  Approximately 100 nanograms of total RNA 
from each sample were dephosphorylated and ligated with pCp-Cy3.  The labeled RNA was then 
hybridized to the Agilent miRNA arrays at 55qC for 20 hours.  The arrays were then scanned 
with the Agilent DNA Microarray scanner. The signals quantified using the Agilent Feature 
Extraction software which has the ability to semi-automatically identify probe spots and present 
the raw data on the fluorescence intensities obtained for each individual pixel within the spot.   
 Finally a supervised hierarchical clustering algorithm was applied comparing those tumors 
with local recurrence with those without local recurrence to see if there was any significantly 
different patterns or if there are any miRNA identified that might be used as a candidate miRNA 
in future studies.  
It is clearly understood that with a sample of only eight cases this was but an early pilot study. 
Provided there is adequate extraction of intact miRNA to perform the mircoarry analysis and 
candidate miRNAs emerge for consideration further analysis on a larger set of tumors would be 
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warranted, which might in turn lead eventually to validation studies. This further work is beyond 
the scope of this PhD thesis.  
7.2.3.6  Ethics approval  
Ethics approval was obtained from the Biomedical Research Ethics Board at the University of 
Saskatchewan (Bio-REB # 09-14). 
7.2.3.7  Statistical analysis 
Data analysis was performed using Agilent Gene Spring GX software version 10.5.1.1.  
Unsupervised clustering was performed on the raw data.  P values were calculated using the 
student t test.  A p value of <0.05 was considered statistically significant.  
7.2.3.8 Results 
7.2.3.8.1 Quality of miRNA extracted  
In order to provide reliable data through microarray testing one must ensure that the samples 
provide sufficient miRNAs for analysis.  The quality and quantity of miRNA isolated from the 
FFPE samples was shown to be adequate for accurate microarray analysis.  Initial analysis using 
spectrophotometry to assess for the quality and purity of total RNA isolates provided 260/280 
and 260/230 ratios indicative of high purity RNA samples.  Quality control analysis of the 
microarray data was performed using quality metrics scores, which assesses various quality 
parameters including background noise, population outliers, signal uniformity and intensity.  For 
each sample the values for each parameter were found to lie within the standards indicative of 
adequate quality.   
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7.2.3.8.2 Unsupervised hierarchical clustering analysis and Candidate miRNAs 
The basis of unsupervised clustering is to group tumors into homogenous classes based on 
gene expression profiles.  866 miRs were represented on the Agilent MicroRNA V3 arrays.  
Tumor samples were analyzed in an unsupervised manner so as to examine the intrinsic structure 
of the dataset and results were summarized in a dendrogram (Figure 7.1).  Unsupervised 
hierarchical clustering failed to identify any miRNA profile amongst the eight samples studied.  
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Figure 7.1 Supervised hierarchical clustering of miRNA expression data with mapping of 
miRNA expression profile. 
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7.2.3.8.3 Supervised Analysis 
The data was further analyzed to assess for individual candidate genes that displayed 
expression changes between the recurrent versus non-recurrent groups.  This was performed 
using Agilent Gene Spring GX.  No miRNAs passed significance analysis, however there were a 
number of miRNAs which did exhibit expression differences between the two groups.  The data 
was analyzed for miRNAs with fold changes 2, 44 miRNAs were found to meet this criterion, 8 
of which had fold changes  3 (Table 7.2). 
Table 7.2: Candidate miRs with fold change greater then 3 
miRNA Fold Change Regulation (Recurrence vs No Local Recurrence) 
miRNA-451 6.541835 Up 
miRNA-363 5.9384456 Down 
miRNA-205 3.9676561 Down 
miRNA-203 3.8479598 Up 
miRNA-224 3.4443598 Up 
miRNA-7 3.406654 Up 
miRNA-18a 3.0821824 Up 
miRNA-1254 3.0308013 Down 
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7.2.3.9 Discussion 
miRNAs are known to be involved the regulation of various cancers including breast 
cancer.  To date the possibility of miRNA profiling predicting local recurrence in early 
stage breast cancer has not been explored and as such offer a novel area of investigation. 
The pilot study conducted for this thesis analyzed the expression of 866 miRNAs in four 
locally recurrent breast cancers and four non-recurrent breast cancers.  Despite the age of 
the samples (ranging from 10-14 years) the quantity and quality of intact miRNAs from 
the PFFE samples was acceptable, supporting the use of miRNA microarray profiling in 
the study of archival FFPE tissues samples stored for up to 14 years. Not surprising given 
the small sample size the two groups failed to cluster in a significant manner but 44 
miRNAs were differentially expressed, 8 of which had at least a 3 fold change. These 
eight candidate miRNA warrant further investigation with one in particular deserving of 
particular attention.  
Of significant interest in local recurrence, miRNA-205 is known to be down regulated 
in breast cancer, and is thought to play a tumor suppressor role.(261) In our study it was 
shown to be down regulated in recurrent cancers by 4.0 fold compared to non recurrent 
cancers. It is known to hinder invasion and metastasis in breast cancer through its 
inhibition of Erb-B3 and VEGF-A.(262) Of particular interest in local recurrence, miR-
205 has been shown to be significantly associated with locoregional recurrence of head 
and neck squamous cell carcinoma, independent of disease severity at diagnosis and 
treatment.(263) These findings certainly point to miR-205 as a suitable candidate for 
further investigations into its role with breast cancer local recurrence.   
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7.2.3.10 Conclusions 
miRNA expression profiling can be done successfully on FFPE tissue samples as old 
at 14 years. The amount of intact miRNA recovered is acceptable. The value of the 
candidate miRNA-205 in particular warrants further study on a larger sample of breast 
specimens.   
7.3 Randomized controlled trial in the modern setting 
7.3.1 Introduction 
While the study done to for this thesis does not demonstrate an increased local 
recurrence rate with a narrow (less than or equal to 2 mm) but negative surgical resection 
margin in early stage breast cancer treated with BCT the modern management of early 
stage cancer has changed significantly from the time that the data from this study was 
collected. As mentioned earlier the retrospective and single institutional nature of the 
study also carries with it limitations. It would be ideal to construct a prospective 
randomized study to confirm the observations of this thesis work in the modern setting.  
7.3.2 Potential study design 
I would suggest a study design in which all patients who present with an early stage 
breast cancer (stage I or II) who are treated with lumpectomy, registered with the 
Saskatoon Cancer Agency, and considered for post-operative adjuvant radiation therapy 
be considered eligible for enrollment. Ideally similar patients registered in other cancer 
centers would also be registered. Those patients who have an initial narrow (less than 2 
mm) surgical resection margin would randomly be assigned to one of three groups 
following appropriate consent—re-excision to obtain a wide surgical resection margin, no 
re-excision but a boost of radiation of 1,600 Gy or no re-excision and no radiation boost. 
Adjuvant radiation and chemotherapy would be administered according to normal 
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protocol. Pathologic reporting would be synoptic according to current guidelines. In 
addition all specimens would undergo genetic assessment with both DNA microarray and 
miRNA microarray as would any local recurrences in order to be able to determine 
whether or not the local recurrence is a true recurrence or a new primary. Information on 
the other variables of interest as determined by the literature review conducted for this 
thesis would be also be collected.  
7.2.4 Sample size 
Given that a the modern local recurrence rate is lower (about half) than it was during 
the time when the data was collected for the study conducted for this thesis the calculated 
number of patients required in each arm would be 400.  
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